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Abstract
Molecular mechanisms of microRNA-1205 in aggressive prostate cancer
by
Michelle K. Naidoo
Advisor: Dr. Olorunseun O. Ogunwobi
Prostate cancer (PCa) is one of the most commonly diagnosed cancers among men in the United
States. High mortality rates of PCa are associated with metastatic castration-resistant prostate
cancer (mCRPC) due to the maintenance of androgen receptor (AR) signaling despite androgen
deprivation therapies (ADTs). Resistance to second generation ADTs leads to the progression of
AR-independent treatment related-neuroendocrine PCa (t-NEPC), which is observed in nearly 1
in 5 men with mCRPC and is associated with very poor outcomes. The 8q24 chromosomal locus
is a region of very high PCa susceptibility that carries genetic variants associated with PCa
aggressiveness. Located at this region is the PVT1 non-protein coding gene, implicated in PCa,
and that encodes microRNA-1205 (miR-1205). As PVT1-encoded miRNAs are largely
understudied, we sought to understand the role of miR-1205 to further implicate the importance of
the 8q24 chromosomal locus in PCa. We observed that miR-1205 is underexpressed in a cohort of
histologically confirmed PCa tissues, when compared to normal tissues and is also underexpressed
in CRPC cells, when compared to non-CRPC cells. Our preliminary data suggest that a synthetic
analog of miR-1205 inhibited tumor volume in a xenograft mouse model of CRPC, suggesting that
miR-1205 may be a tumor suppressor in PCa. To understand the molecular mechanisms of miR1205, we identified and validated FRYL as a molecular target of miR-1205 and demonstrated that
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miR-1205 can regulate FRYL mRNA stability. To identify additional molecular targets of miR1205, a RNA pulldown assay was performed and sequencing of miR-1205 enriched targets
(Arraystar INC) were identified (in collaboration with Dr. Konstantinos Krampis) in various PCa
models. We discovered that miR-1205’s molecular signature may be involved in neural-associated
pathways, including dendrite regulation and cell differentiation. Interestingly, FRYL is also
predicted to regulate dendritic branching and is significantly overexpressed in NEPC tissue when
compared to benign prostate tissues. Therefore, we hypothesized that miR-1205 and FRYL could
be involved in PCa neuroendocrine differentiation (NED), a phenomenon that is observed in tNEPC. Differentiation of PCa luminal cells into AR-negative neuroendocrine cells occurs as a
mechanism of defense towards ADT’s. We examined miR-1205 regulation of FRYL in NED in
vitro by culturing LNCaP androgen sensitive PCa cells under androgen deprivation conditions. We
observed FRYL mRNA overexpresssion and significant underexpression of miR-1205 in LNCaPNED cells when compared to undifferentiated LNCaP cells. To further characterize this
mechanism, a miR-1205 mimic was used to overexpress miR-1205 in LNCaP cells. While FRYL
and NEPC markers (AurA and Neuron specific enolase 2) expression decreased when miR-1205
was overexpressed, FRYL knockdown did not decrease NED markers, suggesting that miR-1205
regulates NED-specific targets in a FRYL-independent manner. In conclusion, this project
provides novel insights into the role of miR-1205 in biological mechanisms that could have clinical
relevance in PCa.
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Chapter 1:
Introduction

1

Prostate cancer
Prostate cancer (PCa) was the second most diagnosed and deadliest cancer in 2020 with an
estimate of 209,512 cases and 32,438 deaths in the United States according to GLOBOCAN20201.
Although men diagnosed with local and regional PCa have a 100% 5-year survival rate, patients
diagnosed with PCa at an advanced stage have a relative 30% 5-year survival rate, indicating that
the spread of the disease is lethal 2. Androgen deprivation therapy (ADT) is critical for patients
that display indications of high-risk localized or metastatic PCa and is currently the most effective
treatment that significantly improves survival rates

3-5

. However, 10-20% of patients develop

castration resistant PCa (CRPC) due to failure of tumor regression upon treatment, in which 33%
with CRPC develop metastatic CRPC (mCRPC) within two years of diagnosis 6-8. While several
next generation hormone treatments, such as abiraternone acetate and enzalutamide, enhances
survival rates for men diagnosed with mCRPC, 20-40% patients do not respond to treatments and
those who initially respond to treatments may acquire secondary resistance 9,10. Better knowledge
on the mechanisms of resistance will provide novel insights into development of better therapeutic
strategies to treat advanced PCa.
PCa is initially a disease of androgen dependence 11,12. Hormones, such as testosterone and
dihydrotestosterone (DHT), are the key androgens that promote the growth and survival of PCa
cells 13. Testosterone is produced from cells in the testis and adrenal cortex, while DHT is mostly
produced in prostatic tissue following the conversion from testosterone

14,15

. These hormones

promote the growth and survival of PCa cells by binding to the ligand binding domain of the
androgen receptor (AR) in the cytoplasm. AR is a nuclear receptor that homodimerizes when
bound to DHT, initiating its activation and subsequent localization to the nucleus

16,17

. In the

nucleus, AR binds to androgen response elements on androgen regulating genes that are
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responsible for the growth, communication, differentiation and proliferation of prostate cells 18-21.
Therefore, major efforts have been initiated into therapeutically targeting androgen production and
AR signaling to disrupt further PCa cell proliferation and growth.
ADTs are treatments that either reduce androgen production through chemical or physical
castration or treatments that block AR signaling with the use of anti-androgens. ADT coupled with
radiotherapy can significantly improve overall survival rates and is the recommended prognosis
for patients that display locally confined low-risk or advanced PCa

22-24

. Although ADTs are

successful in remission of locally high-risk and advanced tumors, the duration of response can
vary up to 2-10 years, in which the development of CRPC eventually progresses. To improve the
outcomes of patients with CRPC, several second-generation ADTs were established for treatment
including abiraterone (inhibits cytochrome P45017A1 enzyme required for androgen synthesis)
and enzalutamide (binds to ligand binding domain of AR and inhibits AR activity). However, 2040% patients do not respond to treatments and those who initially respond to treatments may
acquire secondary resistance 9,10,25. Better knowledge on the mechanisms of resistance will provide
novel insights into development of better therapeutic strategies to treat advanced PCa.
Although AR signaling is not the sole driver of prostate carcinogenesis, almost 80-90% of
PCas are dependent on androgenic activity via AR signaling

12

. CRPC largely develops due to

maintenance of androgen receptor (AR) signaling in PCa cells after initial response to ADTs. AR
signaling is maintained by various mechanisms, including AR amplification and/or presence of
AR ligand domain mutations that lead to the constitutive activation of the AR signaling pathway
26-32

. Moreover, as PCa is a very heterogeneous disease, some patients express rare PCa subtypes

after ADT relapse that are AR-negative and survive with complete independence of AR signaling.

3

Therefore, resistance towards ADTs brings a new challenge for treating men with CRPC and better
understanding of these mechanisms will provide knowledge on how to address PCa heterogeneity.
Neuroendocrine prostate cancer (NEPC)
Luminal secretory cells are found in the epithelium of the prostate and are thought to be
responsible for the initiation of PCa 33-35. These cells show high AR immunoreactivity and express
high levels of AR, compared to the basal cells and neuroendocrine cells in the epithelium

34,36

.

Upon complete androgen obstruction, almost 70% of luminal secretory cells can undergo apoptosis
and procure AR-mediated proliferative inhibition while basal and neuroendocrine cells are largely
unaffected, indicating their independence towards ADTs 37. Therefore, AR-negative cells, such as
basal and neuroendocrine, may gain proliferative advantage to further progress CRPC as a bypass
mechanism because of their ability to thrive in a low-androgen environment. Further understanding
of how this resistant mechanism occurs in AR-negative cells will provide clinicians on how to
assess failure of initial and secondary ADTs when treating CRPC patients that show increased
neuroendocrine proliferation.
Increased proliferation of neuroendocrine PCa cells leads to the development of

NEPC

. Although NEPC is rare (<2% incidence in the United States), men who develop NEPC have very
poor prognosis because of lack of targeted therapies and insufficiently identified biomarkers 38.
The innate role of neuroendocrine cells in the prostate is not well understood, but it is believed to
secrete neuropeptides and growth factors that enhance luminal cell proliferation 34. Amplification
and overexpression of MYCN and AURKA genes have been observed in validated NEPC tissue
and both induce a NEPC-positive phenotype in prostate cells as seen in in vitro and in vivo studies
38,39

. On another note, one of the resistant mechanisms that lead to lethal aggressive disease is a

mechanism known as prostate cancer neuroendocrine differentiation (NED). This phenomenon is
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characterized as PCa cells differentiating and acquiring the phenotypic features of neuroendocrine
cells. This occurrence is observed under androgen deprivation conditions and is often termed
treatment-related NEPC (t-NEPC). The mechanism of NED is thought to occur as a means for
survival against ADTs due to the lack of AR expression and dependence on AR signaling for
survival in neuroendocrine cells. Clinical features of t-NEPC have been observed in patients who
received chemotherapy, including treatments with abiraterone and enzalutamide, indicating its
impact in the heterogeneity of CRPC 40-43. In addition to NED, it is hypothesized that NEPC cell
population can also increase due to cancer stem cells that are increasingly differentiating into
neuroendocrine cells. It is not clear whether NEPC cells increase via cancer stem cells and/or
transdifferentiation in aggressive disease. This field requires further understanding as more men
are diagnosed with PCa, and therefore develop resistant and untreatable cancers. Novel findings
into the mechanisms that drive t-NEPC will not only help create new therapies for treatment, but
also to shed some light on the role of these cells in the prostate.
8q24 chromosomal locus and PVT1
Genome wide association studies (GWAS) has identified over 70 genetic variants that are
associated with high risk for developing PCa 44. The 8q24 chromosomal region was one of the first
regions to be identified and is considered to be the most important PCa susceptibility locus 45. This
region is commonly known to be a “gene desert” due to the lack of protein coding regions

46,47

.

Within the 8q24 chromosomal region lies the PVT1 gene, which encodes a series of alternatively
spliced transcripts along with a cluster of miRNAs (-1204, -1205, -1206, -1207-5p, -1207-3p, and
-1208)

48,49

. These PVT1 encoded miRNAs are spatially distributed across the PVT1 genomic

locus, in which all except miR-1204 are derived from the intronic regions 49. Moreover, PVT1 has
at least six transcription start sites within its locus, indicating that there may be independent
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transcriptional regulation among each PVT1-encoded miRNA (Figure 1)50. As technologies for
detecting and characterizing non-coding RNAs are improving, the PVT1 long non-coding RNA
has been the subject of interest in relation to its association and oncogenic function in cancers 51.
PVT1 is amplified and overexpressed in many cancers and has been reported to function as a
miRNA sponge ultimately inducing proliferation and suppressing apoptosis in cancer cells, such
as non-small cell lung, gastric, ovarian, breast and liver cancers

52-57

. Moreover, our lab has

suggested the potential role of PVT1 as a biomarker and as an important regulatory long noncoding RNA in aggressive prostate cancer 58. However, the importance of PVT1-encoded miRNAs
is largely understudied. The most well described PVT1-encoded miRNA is miR-1204 (miR-1204).
Recent reports have shown the implications of miR-1204 in the promotion of tumor growth in
glioblastoma, hepatocellular carcinoma, breast, and ovarian cancers, indicating a role in
oncogenesis 59,60. Furthermore, our lab has established the clinical significance of miR-1207-3p as
a biomarker and putative therapeutic option through a novel regulatory pathway in prostate cancer
61

. Herein, I sought to investigate whether PVT1-encoding miR-1205 has significance in PCa.

PVT1-encoded miRNAs in cancer and biogenesis
miRNAs comprise about 1-5% of the human genome but regulates about 30% of protein
coding genes

62,63

. These small non-coding RNAs mediate RNA gene silencing through RNA-

interfering (RNAi) pathways. Small RNAs are usually classified by their length, which ranges
from 20-30 nucleotides, and their association with the Argonaute (AGO) family proteins to initiate
RNAi mechanisms. MiRNAs are canonically found within introns of either non-protein coding or
protein-coding transcripts with only small fraction located within exons or intergenically 64. Over
one-third of intronic miRNAs are transcriptionally regulated through distinct promoters from their
host genes, with the loci containing multiple transcription start sites (TSS). As previously
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mentioned, five out of the six annotated PVT1-encoded miRNAs were mapped within intronic
regions of the PVT1 gene locus, including miRs-1205-1208

49

. PVT1 has a total of six TSS’s,

where miR-1204 shares the same promoter as PVT1 and miRs-1205-1208 have distinct TSS’s,
suggesting that PVT1 intronic miRNAs may be regulated independently of the host promoter50.
The regulation of these promoters are not well understood, however, recent evidence shows that
p53 regulates the PVT1/miR-1204 promoter and activates the expression of primary and mature
miR-1204 in human cancer cells60. Moreover, MYC and PVT1 copy number gain is observed in
malignant pleural mesothelioma, in which PVT1 and miR-1204 overexpression is also observed65.
This data suggests that PVT1 and miR-1204 are co-overexpressed because they are regulated by
the same promoter. The underexpression of miR-1207-3p, which does not share the same TSS as
PVT1 and miR-1204 in PCa, suggests that some PVT1-encoded miRNAs can be regulated under
different promoters61. Consistent with this, Pei Li et. al demonstrated that miR-1205 not only
contains an individual TSS site but has multiple binding sites for E2F1 upstream that leads to
attenuation of miR-1205 expression in laryngeal squamous carcinoma cells66, indicating the usage
of a different promoter than the rest of the PVT1. Importantly, most miRNA promoters in the
PVT1 gene have yet to be identified and characterized. Better understanding of miRNA promoter
regulation could accurately demonstrate the role of primary vs. mature miRNA expression in
diseases such as cancer.
RNA polymerase II facilitates transcription of miRNA genes and generates a primarymiRNAs (pri-miRNA) that are characterized as a stem-loop structure containing a stem of 33-35
bps, a terminal hairpin loop and single RNA strands at both 3’ and 5’ ends67. The pri-miRNA then
undergoes further nuclear processing and maturation when Drosha (nuclear RNase III) with its
essential cofactor, DGRC8 (DiGeorge syndrome critical region 8), forms the Microprocessor

7

complex that recognizes the single 3’ and 5’ RNA strands and cleaves ~11bp upstream from the
lower stem region. The recognition of the pri-miRNA lower stem by the Microprocessor defines
the terminus and thus the specificity of a miRNA. Following the Microprocessor cleavage of a primiRNA, the pre-miRNA is exported out of the nucleus via the nucleocytoplasmic transporter
Exportin-5 driven by GTP-bound Ran for further processing into a mature miRNA. Once exported
into the cytoplasm, the pre-miRNA terminal loop is cleaved by the RNase III-type endonuclease
Dicer and a small RNA duplex is generated. Dicer is usually accompanied by co-factor TRBP
(TAR RNA-binding protein) to recognize the 5’ phosphorylated end and 3’ end (via PAZ domain)
and the terminal loop of the pre-miRNA to induce cleavage of pre-miRNA subsequently
generating a discrete size of the small miRNA duplex ranging from 21-25 nucleotides in length.
The small RNA duplex is loaded into the AGO protein, where 5’end of the guide strand interacts
with AGO MID-PIWI domains and the 3’ end interacts with the AGO PAZ domain. The loading
of a miRNA duplex into AGO is sterically placed so the seed region on the guide strand is in a
conformation to facilitate scanning of mRNA target and is known as the pre-RNA inducing
silencing complex (pre-RISC). After formation of the pre-RISC, the passenger strand of the
miRNA duplex unwinds to generate the mature RISC, where the strand with a relatively unstable
5’ terminus is selected as the guide strand, while the remaining passenger strand is immediately
degraded. Translational repression of miRNA target mRNAs mostly occurs in animals in contrast
to endonucleolytic cleavage that occurs primarily in plant cells. However, endonucleolytic
cleavage of mRNA targets is not entirely exclusive to plant cells, as if there is nearly perfect
binding between the miRNA seed region and mRNA target region, direct mRNA cleavage can
occur. Full or nearly complementary binding between the miRNA seed region and mRNA target
leads to target slicing/cleavage through the PIWI domain of AGO. In the case of partial

8

complementarity between the miRNA seed region and mRNA target degradation occurs by
translational repression and/or deadenylation of mRNA68. The mechanisms of translational
repression are not well understood in contrast to degradation of mRNA targets through
deadenylation. Glycine-tryptophan protein of 183 kDa (GW182), a component of mature RISC,
mediates deadenylation through interactions with AGO, other components in RISC and the
poly(A) binding (PABP) protein, which recruits CCR4 and CAF1 deadenylases, leading to mRNA
degradation. Each miRNA can have an average of 200 mRNA targets, proving their value in
regulating multiple cellular processes

69

. Moreover, miRNAs are deregulated in many cancers,

implicating their role in tumor progression. Characterization of miRNA signatures for cancers
could lead to effective and specific development of cancer therapeutics.
The goals for this research project are to better understand how PVT1-encoded miR-1205
may play a role in PCa. Huppi et.al identified PVT1-enocoded miRNAs and discovered that miR1205 is expressed at very low levels in many cancer cell lines, suggesting that loss of miR-1205
could play a role in tumorigenesis

49,59

. However, those studies did not include PCa cell lines.

Additionally, it was previously reported that miR-1205 is expressed at higher levels in the thymus
when compared to other PVT1-encoded miRNAs, suggesting a putative role in normal cell
differentiation 59. Therefore, we are interested in elucidating the molecular mechanisms of miR1205 and to understand its putative role in PCa tumorigenesis.

9

Figure 1: The 8q24 chromosomal locus. Graphical representation of 8q24.21 chromosomal locus focused
on the PVT1 and MYC gene. PVT1 encodes a cluster of miRNAs including miR-1204, -1205, -1206, 1207-3p/5p and -1208. Black bars represent Transcription Start Sites (TSS) indicating promoter locations
and orange bars represent PVT1 annotated exons.
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Chapter 2:
Materials and Methods

11

Cells and cell culture conditions
Cell culture of human RWPE-1 (normal prostate epithelial cells) and WPE1-NA22
(indolent PCa epithelial cells) were maintained in Kerantinocyte medium supplemented with 0.05
mg/ml bovine pituitary extract, 5ng/ml epidermal growth factor (EGF) and 1% PenicillinStreptomycin (PS)70

71

. MDA PCa 2b (metastatic PCa adenocarcinoma epithelial cells) were

cultured in F-12K medium supplemented with 20% non heat-inactivated fetal bovine serum (FBS),
25 ng/ml cholera toxin, 10 ng/ml mouse EGF, 0.005 mM phosphoethanolamine, 100 pg/ml
hydrocortisone, 45 nM sodium selenite, 0.005 mg/ml human recombinant insulin, and 1% PS 72.
PC-3 (androgen-independent metastatic PCa cells) were cultured with F-12K medium
supplemented with 10% FBS and 1% PS

73

. LNCaP (androgen-sensitive PCa cells) and 22Rv1

(human androgen-insensitive PCa cells) were cultured in RPMI 1640 supplemented with 10% heat
inactivated FBS and 1% PS 74 75 76. C4-2B (human androgen-insensitive PCa cells) were cultured
in DMEM/F12(4:1) supplemented with, 10% heat-inactivated FBS, 1% penicillin/streptomycin,
5µg/ml human insulin, 13.65 pg/ml triiodothyronine, 4.4 µg/ml human apo-transferrin, 0.244
µg/ml d-biotin, and 12.5 µg/ml adenine. The C4-2B cell line is a well validated and widely
recognized model of CRPC obtained from MD Anderson Cancer Center under a materials transfer
agreement with Hunter College of The City University of New York

77

. All PCa cell line

characteristics are represented in Table 2.1.
LNCaP neuroendocrine-differentiated cells
RPMI

1640

medium

containing

10%

charcoal-stripped

FBS

and

1%

penicillin/streptomycin was used to differentiate LNCaP cells into neuroendocrine-like PCa cells.
Control LNCaP cells were seeded in a 10cm culture dish and were maintained with RPMI 1640

12

medium containing 10% heat inactivated FBS and 1% penicillin/streptomycin. LNCaP and
LNCaP-NED cells were cultured for 10 days, and pellets were collected for downstream analysis.

13

PCa
Cell lines

Indolent
Disease

Normal

Androge

Prostat

n

e

sensitive

X

X

Aggressiv

Androgen

e disease

References
insensitive

Bello et al.,
RWPE-1

1997
WPE1-

Webber et
X

X

NA22

al., 2001

MDA-

Navone et
X

X

Pca-2b

al., 1997
X
Kaighn et

PC-3

X

(AR
al., 1979
negative)
Horoszewic

LNCaP

X

X
z et al., 1980
Thalmann

C4-2B

X

X
et al., 2000
Sramkoski

22RV1

X

X
et al., 1999

Table 2.1: PCa cell line models. All cell lines were characterized according to disease stage and androgen
sensitivities.
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Patient Cohorts
Tissues were collected by Drs. Akintunde T. Orunmuyi and E. Oluwabunmi OlapadeOlaopa in compliance with Institutional Ethics Board approved protocol at the City University of
New York and University of Ibadan (Figures 1A and 4B). All experiments were performed in
accordance with relevant guidelines and regulations. Informed consent was acquired for all
participants. Deidentified frozen tissue was obtained from prostatectomy or transrectal
ultrasounded-guided biopsies in patients from University of Ibadan (Nigeria) after abnormal digital
rectal exam. All tissues were histologically identified by a pathologist as normal prostatic (adjacent
normal tissue, n=22), benign prostatic hyperplasia (Gleason score < 7 with pathologic stage of T1
or T2 and 2, n=42), or PCa tissue (Gleason score >=7 and/or have a pathologic stage of T3 or T4,
n=26). RNA extraction, cDNA synthesis and RT-qPCR was performed to analyze mRNA
expression of FRYL and mature transcripts of miR-1205.
In a separate study, FRYL expression was examined in a RNA-seq analysis of PCa and
adjacent normal tissue (n=14) of a Chinese population using the galaxy web platform
(https://usegalaxy.org) in collaboration with Dr. Konstantinos Krampis78. The short
oligonucleotide analysis package aligner (SOAP2) was used to map the reads to the human genome
(hg18).
Lastly, we examined the expression levels of FRYL in a Weill Cornell Medicine (WCM)
cohort of histologically confirmed (hematoxylin and eosin stained slides reviewed by boardcertified pathologists): benign prostate samples (n=29), localized PCa (n=66), castration resistance
adenocarcinomas (CRPC, n=73), and NEPC (n=36) samples whose transcriptome was profiled by
RNA-seq in collaboration with Dr. Andrea Sboner (Englander Institute for Precision Medicine,
WMC) (Fig. 3)79,80. We aligned all reads against the human genome sequence build hg19
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(http://hgdownload.soe.ucsc.edu/goldenPath/hg19/bigZips) with STAR_2.4.0f1

81

and used

SAMTOOLS v0.1.19 82 for sorting and indexing reads. We estimated expression values (FPMKs
– fragments per million reads per kilobase of exons) with Cufflinks (2.0.2) 83 based on GENCODE
v19 84 gene annotation. Since the sequenced samples from the published datasets were processed
using different library preps, i.e. poly-A selection or ribosomal depletion, we normalized FPKMs
via ComBat
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from sva bioconductor package

86

. This way the differences due to the library

preparation methods are reduced.
Total RNA isolation and quantitative real-time polymerase chain reaction (qRT-PCR)
analysis
RNA isolation, cDNA synthesis, and qRT-PCR were performed as previously described
75

. All experiments were performed three times in quadruplicates. The expression of genes was

normalized to the expression of GAPDH. GAPDH and FRYL human primers were purchased from
Sigma-Aldrich (St. Louis, MO, U.S.A.). Primer sequences for FRYL: Forward: 5’-AGC ATT
GTA GCT GTT GGT TTGT; Reverse: 5’- AGG GCA ATT CAA GAA GGT AACA.
Small RNA isolation and quantitative real-time polymerase chain reaction (qRT-PCR)
analysis (detection of mature miRNA)
miRNAs were purified using the mirVanaTM miRNA isolation kit from Ambion (life
technologies). First, cells are lysed in a denaturing lysis buffer and RNA is isolated against DNA
and other biomolecules using Acid-Phenol:Chloroform. To enrich small RNAs, ethanol is added
to bring the extract to 25%-ethanol concentrate and is then passed through a glass-fiber filter that
traps large RNAs. The filtrate containing small RNAs is collected, and the ethanol concentration
is increased to 55% and passed through a new glass-fiber filter. The small RNA bound to the glass-
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fiber filter is then washed a few times and then eluted with a low ionic strength solution. Purity of
RNA and quantification is determined using the NanoDrop spectrophotometer.
Mature miRNAs are reverse transcribed into cDNA using the miScript II RT kit from
Qiagen. First, mature miRNAs, which are not polyadenylated in nature, are polyadenylated with a
poly(A) polymerase. Oligo-dT primers with a 3’ degenerate anchor and a universal tag sequence
on the 5’ end is used to amplify the small polyadenylated miRNA. A HiSpec buffer that is a patentpending formulation that selectively converts mature miRNAs into cDNA is also used to aid in
conversion of mature miRNA to cDNA. The miSript SYBR Green PCR kit from Qiagen was used
to perform q-PCR analysis for miR-1205 expression. The miR-1205 miScript Primer assay
(forward primer) or RNU6B (negative control forward primer) and the miScript Universal Primer
(reverse primer) was used with SYBR green to perform q-PCR analysis. Relative expression of
miR-1205 was determined using the delta-delta Ct method. The expression of miR-1205 was
normalized to the expression of RNU6B.
Synthesis of synthetic miR-1205 analogs and control oligonucleotides
Synthesis of negative control scramble oligonucleotides (NB1) and synthetic miR-1205 analogs
(NB1205) was carried out on an automated synthesizer using standard protocols and HPLCpurified. Purified products are stored as lyophilized powder at -20 ˚C until use.
Transfections of oligonucleotides and siRNAs
Transfection of miR-1205 mimic, miR-1205 inhibitor, NB1 and NB1205 were performed as
previously described 75. miR-1205 mimic (MISSION miRNA Mimic – hsa-miR-1205, HMI0063),
miR-1205 inhibitor (MISSION Synthetic miRNA Inhibitor – hsa-miR-1205, HSTUD0063) and
FRYL siRNA were purchased from Sigma-Aldrich. Transfection of siRNAs were performed as
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described 87. Negative control scramble siRNAs which do not lead to specific degradation of any
known mRNA were used as negative controls 75.
Western blotting
Western blotting was performed as described previously

75

. Primary antibodies against human

FRYL: PA5-56644 (ThermoFisher Scientific, U.S.A), Aurora A: 14475 (Cell Signaling), NSE:
NB200-421 (Novus Biologicals), human GAPDH: 5174 (Cell Signaling) and alpha tubulin: sc32293 (Santa Cruz Biotechnology). Secondary antibodies used were either against mouse or rabbit
(LI-COR, St. Louis, MO, U.S.A). Western blot quantifications were performed with either the
Odyssey imager, Image Studio version or ImageJ.
Assessment of effect of NB1 and NB1205 on in vivo CRPC tumor growth
We evaluated the effect of NB1205 and NB1 on in vivo tumor growth. All animal studies were
approved by the Institutional Animal Care and Use Committee at Weill Cornell Medicine and were
performed in accordance with relevant guidelines and regulations. Male NOD/SCID gamma NSG)
mice were implanted subcutaneously into the right flank with 1 x 106 C4-2B CRPC cells.
Approximately 6 weeks after C4-2B cells implantations, mice were randomized into two groups
of three mice per group: Group 1: (NB1) and Group (NB1205). Both groups were administered
with daily subcutaneous injections of 100 µl of either 100 nM of control scramble duplex (NB1)
or miR-1205 duplex (NB1205) for 10 days. Tumor volume (length, width, height) was determined
using a vernier caliper and a scale was used to measure mouse body weight daily. All tumorbearing mice were euthanized at day 70.
Annexin V/propidium iodide staining
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Annexin V-FITC and propidium iodide staining assay was performed using ApoScreen® Annexin
V Apoptosis Kit-FITC (Catalog. No. 10010-02, SouthernBiotech). LNCaP and C4-2B cells were
transfected with either the control scramble oligonucleotide or miR-1205 mimic and after 48 hours
the cells were harvested, stained and examined using flow cytometry.
RNA pulldown and RNA sequencing
RNA pulldown was similarly performed as previously described with some modifications 75. The
DynaBeads Myone Streptavidin C1 (Ref: 65001, ThermoFisher Scientific) were washed three
times with bead wash buffer (5mM Tris-Cl pH 7.5, 0.5 mM EDTA, and 1M NaCl) and blocked
overnight (1 µg/µl BSA and 1 µg/µl yeast tRNA). Cells transfected with 7nM of the miR-1205 or
scramble biotinylated duplex were harvested and lysed after 24 hours. The lysate and beads were
mixed and incubated overnight at 4˚C. The following day, beads were washed, and target mRNA
associated with the duplex was isolated using TRIzol (Ref:15596026, ThermoFisher Scientific).
To determine enrichment of target mRNA, qRT-PCR analysis was performed to detect FRYL or
AURKA in control (transfected with NB1) and experimental lysate (transfected with NB1205).
To identify the molecular targets of miR-1205, the isolated RNA was sequenced by ArrayStar,
Inc. Total RNA was either enriched using oligo(dT) magnetic beads or by depleting ribosomal
RNA. Illumina kits were used for RNA-seq library preparation, which includes the processing of
RNA fragmentation, random hexamer priming for single strand cDNA conversion, second strand
synthesis with dUTP, end-repairing, A-tailing, adaptor ligation, and library PCR amplification.
Qualification of libraries were performed using Agilent 2100 Bioanalyzer and quantification was
performed by qPCR absolute quantification. The sequencing was performed using Illumina Hiseq
4000. Sequence reads were aligned to hg38 reference genome and MACS2 was used to identify
areas of the genome enriched with the aligned reads (peak calling). CHIP-seeker was used to
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annotate peaks of enriched miR-1205 targets in collaboration with Dennis Huang and Dr.
Konstantinos Krampis (Hunter College, CUNY).
Luciferase reporter assay
Human FRYL (HmiT008154-MT06) and miRNA target clone control vector for pEZX-MT06
were purchased from GenecopoeiaTM, Rockville, MD, USA. Cells were seeded in a 24 well plate
and co-transfected with either a negative control oligonucleotide (MISSION Negative Control 1,
NSTUD001), miR-1205 mimic, or miR-1205 mutant and/or miRNA target clone control vector or
FRYL 3’UTR target clone vector. The miR-1205 mutant contains nucleotide changes within the
seed region of the mature miR-1205 strand (UGC to CUG). Lysates were analyzed using the LucPairTM Duo-Luciferase Assay kit 2.0 (LF001, Genecopoeia). Luminescence was detected using the
SpectraMax i3x multi-mode detection platform.
Statistical analysis
Data was collected from multiple independent experiments. All results are presented as mean ±
standard deviation. Unless otherwise indicated, analysis of statistical significance of differences
between groups was performed using two-tailed Student’s t-test, and only values with p < 0.05
were considered significant. Data presented in figures 3.1 and 4.2 were analyzed using one-way
ANOVA test, multiple comparison Tukey post hoc test and/or independent student’s t-test as
described 75. Data presented in all other figures were analyzed using the student’s t-test.
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Chapter 3:
MicroRNA-1205 regulation of FRYL in prostate cancer cells
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Introduction
The underlying causes of prostate cancer (PCa) range from various endogenous or
exogenous factors including race and familial genetics to diet, socioeconomic status and
environmental agents. However, one of the highest risks for developing PCa are due to genetic
factors, which account for 40% of PCas reported88. Hundreds of single nucleotide polymorphisms
(SNPs) at different loci have been identified in Genome wide association studies (GWAS) that
strongly associate with PCa susceptibilities89. One of the first GWAS studies linked SNP variants
within the 8q24 chromosomal region to PCa susceptibility and subsequent reports further
associated these SNPs to additional cancer phenotypes including breast, colorectal and bladder
cancers90-94. However, the functional characterization of cancer susceptibility associated SNPs
within a genetic loci, including 8q24, are not entirely understood. Better understanding on the role
of genetic variants and the subsequent functional outcome could reveal insight on the progression
of diseases such as cancer.
Nearly 90% of SNPs associated with a phenotype were identified within non-protein
coding regions including intronic, promoter, enhancer/insulator, and non-coding genetic loci that
generate long non-coding RNA and miRNAs95. Interestingly, the 8q24 chromosomal region is
commonly known to be a “gene desert” due to the lack of protein coding genes

46,47

. There is a

total of five protein coding genes, twelve long non-coding RNAs and several miRNAs located
within the 8q24.21 region. Most notably, the MYC oncogene is located within this region and
could be the most obvious link to the cancer-associated genetic variants as it is one of the most
frequently dysregulated genes in cancers96. However, MYC amplification is usually accompanied
with PVT1 amplification in cancers, shedding light on the importance of surrounding non-coding
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genes within 8q2497,98. Additional investigation into functionality of non-coding transcripts, such
as PVT1, could further implicate the importance of cancer associated SNPS within 8q24.
The PVT1 gene is located directly 3’ of MYC. PVT1 and MYC co-amplification is
observed in many cancers, however there is evidence that they independently contribute to
disease99. The PVT1 gene produces a series of alternatively spliced transcripts that function as a
regulatory long non-coding RNA and a cluster of miRNAs (-1204, -1205, -1206, -1207-3p, -12075p, and -1208) 48,49,51. PVT1 expression is significantly higher in cancer cell lines when compared
to human primary cells and tissues, suggesting oncogenic properties99. PVT1 long non-coding
RNAs are multifunctional and have been reported to act as a competitive-endogenous RNA by
sponging miRNAs, interact and stabilize the c-MYC protein, and bind to histone methyltransferase
EZH2 to induce trimethylation leading to transcriptional repression of miR-200b52-56,58,100,101.
PVT1-encoded miRNAs are also linked to disease. Recent reports have shown the implications of
miR-1204 in the suppression of tumor growth, suggesting a role in oncogenesis 59,60. Interestingly,
it has been reported that PVT1 amplification increases PVT1 and mature miR-1204 expression but
not other PVT1-encoded mature miRNAs levels, indicating that PVT1 and miR-1204 share
promoter but not the other miRNAs encoded by PVT1 gene60,65. Consistent with this, our lab
demonstrated that while PVT1 transcript is overexpressed in PCa cells, PVT1-encoded miR-12073p is underexpressed playing novel regulatory roles in PCa61. This indicates that miR-1207-3p
does not share the same promoter that regulates the expression of the PVT1 long non-coding
RNA61,102,103. The importance of other PVT1-encoded miRNAs, such as miR-1205, -1206, and 1208, are largely understudied and a more in-depth investigation will further demonstrate the
importance of the 8q24 chromosomal locus in PCa.
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Due to the increasing evidence of PVT1-encoded miRNAs in cancer, we were interested
in elucidating the role of

miR-1205 in cancer. It was previously reported that miR-1205 is

expressed at very low levels among cancer cell lines (not including PCa cell lines).

49,59

.

Furthermore, a recent report showed that exogenous expression of miR-1205 significantly reduces
in vivo tumor growth of laryngeal squamous cell carcinoma and non-small cell lung cancer
strongly suggesting that miR-1205 may be a tumor suppressor66,104. The aim of this chapter is to
investigate the role of miR-1205 in PCa by examining/validating its binding to mRNA targets and
regulation of expression. These studies will contribute to our understanding of the role of 8q24
chromosomal region and PVT1 locus in PCa risk.
Results
3.1. MicroRNA-1205 is underexpressed in PCa tissue and cells
To examine the role of miR-1205 in PCa its expression was assessed in a cohort of
histologically confirmed normal prostatic (n=22), benign prostatic hyperplasia (abnormal digital
rectal exam, Gleason score < 7 with pathologic stage of T1 or T2 and 2, n=42), and PCa (Gleason
score ≥ 7 and/or have a pathologic stage of T3 or T4, n=26) tissues that were
obtained from prostatectomy or transrectal ultrasound-guided biopsies. One-way ANOVA
analysis determined changes in the relative expression of miR-1205 between groups (F (2,87) =
1.153). A Tukey post hoc test revealed that miR-1205 expression was lower in benign tissue (4.61
± 7.5) and PCa tissue (3.39 ± 3.53) than in normal prostatic tissue (6.55 ± 9.5) (Fig. 3.1A). This
data suggests that miR-1205 is underexpressed in human prostatic tumor tissue, suggesting that
loss of miR-1205 function may drive progression of solid prostatic tumors. To further elucidate
the expression levels of miR-1205 in PCa, we assessed the levels of mature miR-1205 expression
in a panel of human PCa cell lines including RWPE-1 (normal prostate epithelial cells) 70, WPE1-
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NA22 (RWPE-1 cells transformed with MNU; non-invasive)

71

, MDA-PCa-2b (PCa

adenocarcinoma) 72, PC-3 (small cell prostatic carcinoma) 105,106, LNCaP (androgen-sensitive PCa
adenocarcinoma)

74

, C4-2B (androgen-insensitive PCa adenocarcinoma)

(androgen-insensitive PCa adenocarcinoma)

76,108

107

, and 22RV1

. An overall significant decrease of miR-1205

expression was observed in PCa cells when compared to normal epithelial RWPE-1 cells (Fig.
3.1B). Interestingly, mature miR-1205 expression decreased in WPE1-NA22 cells (low-invasive
capabilities) and MDA-PCa-2b cells (benign prostatic hyperplasia tissue), suggesting that loss of
miR-1205 may be an early event in tumor progression. Moreover, miR-1205 mature expression
was also low in PC-3 (90% ±10, a model of androgen-negative with NEPC), LNCaP (80%±15),
C4-2B (80%±5), and 22RV1 (80%±14) cells when compared to RWPE-1 cells, suggesting that
miR-1205 may play a role in aggressive PCa progression. Altogether, my results indicate that
underexpression of miR-1205 in PCa cells may be a sign of tumor suppressive functions loss that
could drive PCa tumorigenesis.
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Figure 3.1: miR-1205 mature transcript is underexpressed in PCa tissues and cells. (a) RNA expression
was determined by RT-qPCR from a cohort of histologically confirmed normal prostatic (n=22), benign
prostatic hyperplasia (n=42), and PCa (n=26) histologically confirmed tissues obtained from prostatectomy
or transrectal ultrasound-guided biopsies. Tissues were collected in compliance with Institutional Ethics
Board approved protocol. One-way ANOVA analysis determined changes in the relative expression of
miR-1205 between groups (F(2,87) = 1.153) and a Tukey post hoc test revealed decreased miR-1205
expression in benign (4.61 ± 7.5) and malignant tumors (3.39 ± 3.53) when compared to normal tissues
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(6.55 ± 9.5). (b) RWPE-1, WPE1-NA22, MDA-PCa-2b, PC-3, LNCaP, C4-2B, and 22RV1 cells were used
to study the expression of miR-1205 in PCa. RT-qPCR analysis showed a significant decrease of mature
miR-1205 RNA expression in PCa cells when compared to normal epithelial RWPE-1 cells. *p<0.05,
**p<0.01, ***p<0.001, and ****p<0.0001 compared to the control. Data is presented as mean and bars
represent mean +/- SD (n=3).
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3.2. MicroRNA-1205 synthetic analog, NB1205, suppresses tumor growth in a xenograft CRPC
mouse model
To assess whether miR-1205 is involved in tumor suppression in PCa, we investigated the
function of miR-1205 in vitro by examining its effect on proliferation and apoptosis of PCa cells.
We designed a synthetic biotinylated miR-1205 duplex (NB1205, patent pending) and a control
synthetic biotinylated scramble duplex (NB1) to be used as tools for studying the function of miR1205. As CRPC is a very aggressive form of PCa and has low expression of miR-1205, we began
examining the effect of miR-1205 in cellular functions using CRPC C4-2B cells to assess
proliferation, apoptosis and in vivo CRPC tumor growth. MTT assays revealed that C4-2B cells
transfected with NB1205 did not significantly affect cell proliferation when compared to cells
transfected with NB1, suggesting that miR-1205 may not affect the proliferation of PCa cells (Fig.
3.2A). However, when examining apoptotic markers, we observed an increase in cleaved caspase
7 and cleaved PARP in C4-2B cells overexpressing miR-1205, indicating that exogenous delivery
of miR-1205 induces DNA damage and activates the apoptotic pathway (Fig. 3.2B). To further
support the role of miR-1205 in apoptosis, LNCaP and C4-2B cells transfected with a miR-1205
mimic and control scramble oligonucleotide were stained with Annexin V-FITC and propidium
iodide. We observed a significant increase of cleaved PARP, an indicative of apoptosis occurrence,
in C4-2B cells overexpressing miR-1205 when compared to cells transfected with a negative
control scramble oligonucleotide (Figure 3.2C). Altogether, this data suggests that miR-1205 may
sensitize apoptosis in CRPC cells (C4-2B) when compared to androgen-sensitive cells (LNCaP).
We next performed an in vivo study to determine whether miR-1205 can suppress tumorigenesis
in PCa. A limited number of mice were xenografted with CRPC tumors using C4-2B cells and
treated with NB1205 (n=3) or NB1 (n=3). While the three mice treated with NB1205 displayed
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smaller tumor volumes (one-way ANOVA (F (1,18) = 4.414, p = 3.4853E-0)), when compared to
one of the three mice intervened with NB1 (n=3, Fig. 3.3A-B), the other two mice intervened with
NB1 displayed tumors of similar size yet retained growth from days 7-10 when compared to the
mice treated with NB1205. As it is possible that the mouse with the highest tumor volume may be
an outlier, more animals should be analyzed to confirm the preliminary data that suggests that the
synthetic analog of miR-1205 can inhibit tumor growth. These preliminary studies suggest that
miR-1205 may inhibit tumor growth of CRPC PCa tumors in mice.
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Figure 3.2: MiR-1205 does not inhibit proliferation but induces apoptosis. (a) MTT assay revealed no
significant changes in proliferation when a synthetic analog of miR-1205 (NB1205) was introduced in C42B cells compared to the control scramble oligonucleotide (NB1). (b) LNCaP and C4-2B cells transfected
with miR-1205 mimic lead to an increased activation of the executioner caspase 7 and PARP cleavage when
compared to cells transfected with NB1. Histogram represents quantification of caspase 7, cleaved caspase
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7, full length PARP and cleaved PARP normalized to GAPDH. Data is represented as mean +/- SD (n=3).
(c) The effect of miR-1205 overexpression on apoptosis was further assessed with AnnexinV/PI staining in
LNCaP and C4-2B cells. Overexpression of miR-1205 led to an increase in C4-2B cells when compared to
cells transfected with a negative control scramble. The scatter plot presented is representative of one of
three experiments performed demonstrating unstained cells (lower left quadrant), Annexin V + cells (lower
right quadrant), Annexin V/PI+ (upper right quadrant) and PI+ (upper left quadrant). Histogram represents
percentage of cells gated for Annexin V-FITC or Annexin V-FITC/PI and normalized to scramble. Data is
represented as mean +/- SD (n=3).
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Figure 3.3: Synthetic analog of miR-1205 may inhibit tumor growth in mice. Male NOD/SCID gamma
mice were subcutaneously implanted with C42B CRPC cells. (a) Mice were randomized into two groups
of 3 mice each and administered NB1 (green) or NB1205 (blue) for 10 days (dosage of 100 mM). Effects
were assessed by daily measurements of tumor volume. (b) Inhibition of tumor growth was observed in
mice treated with NB1205. Data is presented as average of tumor volume for each day of intervention
among each group. There was a statistically significant difference between NB1 (green) and NB1205 (blue)
groups from days 1-10 as determined by one-way ANOVA (F(1,18) = 4.414, p = 3.4853E-05).
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3.3 FRYL is identified as a downstream molecular target of miR-1205
To further investigate the tumor suppressive effects of miR-1205 in PCa, putative targets of miR1205 were examined using miRNA molecular target predication algorithms (such as miRBase and
miRDB). Each target was screened using the galaxy web platform (https://usegalaxy.org) for
differential expression patterns in PCa. Consequently, Fry-like (FRYL) was identified as a putative
target of miR-1205. Very little is known about FRYL, however, the c-terminus of FRYL is often
observed to be fused to the mixed lineage leukemia (MLL) gene associated with treatment related
acute lymphoblastic leukemia (ALL) 109,110. FRYL has almost identical functional domains to the
well characterized Fry protein, which functions as protein involved in many processes including
cell polarization during morphogenesis, dendritic branching and tiling, spindle organization during
division and regulating gene expression

111

. However, the function of FRYL as a target of miR-

1205 has never been characterized, and FRYL’s relevance in PCa remains unknown.
To examine the differential expression patterns of FRYL in PCa, we first evaluated the
mRNA expression of FRYL by RNA sequencing analysis obtained from a subset of prostate
tissues including benign prostatic hyperplasia (n=29), PCa adenocarcinoma (n=66), CRPC (n=73)
and NEPC (n=36) obtained from a Weill Cornell Medicine cohort in collaboration with Dr. Andrea
Sboner from Weill Cornell Medicine (Fig. 3.4A-B). All tissues were histologically confirmed by
a board-certified pathologist. FRYL expression is significantly higher in CRPC and NEPC patient
tumor samples when compared to prostate benign tumors (Wilcoxon test; benign versus CRPC
p=6.6e-05, benign versus NEPC p= 0.00025, PCa versus CRPC p=8.5e-07, and PCa versus NEPC
p= 4.5e-05). Additionally, we performed whole transcriptome analysis using the Galaxy Web
platform in collaboration with Dr. Konstantinos Krampis on primary PCa and adjacent normal
tissue obtained from fourteen PCa patients from a Chinese population112. We observed FRYL
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mRNA overexpression in PCa tissuewhen compared to normal tissue, further implicating a
putative role of FRYL in PCa (Fig. 3.5A)112. Moreover, FRYL overexpression was observed in
PCa tissues when compared to normal prostatic tissues (using the same cohort of patients from
Figure 1) (Fig. 3.5B). FRYL mRNA expression in benign prostatic hyperplasia tissues are low
when compared to PCa tissues (Fig. 3.5B), while mature miR-1205 expression is low in both
benign and PCa tissues (Fig. 3.1). This observation suggests that FRYL might be negatively
regulated by other mechanisms that do not include miR-1205 in early prostate tumor growth, and
it may acquire a gain of function in PCa progression by a miR-1205-mediated mechanism.
Altogether, the FRYL expression among all three cohorts demonstrates for the first time that FRYL
is overexpressed in PCa, and significantly overexpressed in aggressive PCas (CRPC and NEPC,
Fig. 3.4). Lastly, we observed overexpression of FRYL protein in CRPC C4-2B and small cell
prostate adenocarcinoma PC-3 cells when compared to androgen-sensitive LNCaP cells,
indicating a putative role of FRYL in aggressive PCa (Fig. 3.5C). As mentioned before in the tissue
analysis (Fig. 3.5B), there is a lack of correlation between the expression of FRYL protein in
LNCaP, C4-2B, and PC-3 cells (Fig. 3.5C) and the levels of miR-1205 (Fig. 3.1), suggesting that
FRYL protein expression may be regulated by different mechanisms in different stages/types of
PCa. Future studies will include examining the regulation of FRYL mRNA and protein expression
in multiple prostate cell models including RWPE-1 non-tumorigenic prostate epithelial cells and
C4-2B CRPC cells.
Next, to determine if miR-1205 regulates FRYL expression, PC-3 and LNCaP cells were
transfected with a synthetic analog of miR-1205, NB1205, and a miR-1205 inhibitor (Fig. 3.5D).
We observed an inhibition of FRYL protein expression in response to exogenous NB1205
transfected into both PC-3 and LNCaP cells when compared to cell transfected the synthetic
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scramble analog, NB1. Next, PC-3 and LNCaP cells were transfected with a miR-1205 inhibitor,
which did not lead to a significant upregulation of FRYL protein expression; this can potentially
be due to the low levels of mature miR-1205 in LNCaP and PC-3 cells (Fig. 3.1). Together, these
results suggest that miR-1205 may be regulating FRYL leading to translational repression in some
cellular backgrounds.
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Figure 3.4: Expression of FRYL in the WCM cohort. (a) The waterfall plot shows the median-scaled values
of FRYL FPKMs across the cohort for each sub-group (benign, PCa, CRPC, and NEPC) and (b) the
boxplots illustrate the absolute distribution of the log-2 transformed expression levels. The expression of
FRYL is significantly upregulated in advanced prostate cancers (CRPC, NEPC) compared to either benign
prostate or localized PCa tumors. Pairwise comparisons (Wilxocon test) were performed to determine
significance (p-value).
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Figure 3.5: FRYL is overexpressed in PCa and is regulated by miR-1205 in some cellular backgrounds.
(a) FRYL was significantly overexpressed in some PCa tissues when compared to adjacent normal tissues
(ANOVA (F(1,22) = 4.3, p = 0.009) obtained from a Chinese population using the Galaxy Web Platform.
(b) Using the same cohort of tissues in Fig. 3.1A, FRYL mRNA overexpression was observed in PCa tissues
when compared to normal prostatic tissues. (c) Western blot analysis of FRYL in androgen-sensitive
LNCaP cells, CRPC C4-2B cells and small cell prostate carcinoma PC-3 cells. (d) Western blot analysis of
FRYL protein expression in PC-3 and LNCaP cells after overexpression or inhibition of miR-1205 with
NB1205 and miR-1205 inhibitor, respectively. This experiment represents only one trial (n=1).
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3.4. Validation of FRYL as a direct molecular target of miR-1205
To validate if FRYL is a downstream molecular target of miR-1205, a Luc-Pair DuoLuciferase Assay was performed to determine whether miR-1205 may regulate FRYL through the
3’UTR. C4-2B and PC3 cells were either transfected with Genecopoeia pEZX-MT06 miRNA
reporter containing the 3’UTR of FRYL or an empty vector (Fig. 3.6A). Additionally, cells were
co-transfected with either a non-targeting scramble negative control or a miR-1205 mimic (Fig.
3.6A). Overall, a significant decrease in luciferase activity was observed in C4-2B and PC-3 cells
transfected with miR-1205 mimic and the miRNA luciferase reporter construct containing the
3’UTR of FRYL, indicating that miR-1205 may regulate FRYL expression by binding to the
3’UTR (Fig. 3.6A).
The 3’UTR of FRYL contains a total of three putative binding sites to the seed region of
miR-1205 (Fig. 3.7A). To further examine miR-1205 regulation of FRYL 3’UTR across different
PCa models, we used a mutant miR-1205 duplex containing a three-nucleotide change (5’ UGC
3’ to 5’ CUG 3’) within the seed region of miR-1205 co-transfected with the FRYL 3’UTR
luciferase expressing vector into LNCaP cells. The miR-1205 mutation is designed to interrupt
specific binding to the three miR-1205 complementary sites within the 3’UTR of FRYL (Fig.
3.7B). We observed a significant decrease in luciferase activity in cells co-transfected with the
miR-1205 mimic and the luciferase vector containing the 3’UTR of FRYL in LNCaP cells (Fig.
3.7). This is similar to the results observed in C4-2B and PC-3 cells (Fig. 3.6A). Moreover, cells
transfected with 3’UTR FRYL luciferase vector showed similar levels of luciferase activity when
co-transfected with either the miR-1205 mutant duplex or a negative control miRNA, supporting
the idea that the miR-1205 can control the expression of FRYL by its 3’UTR. Future work will
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further validate specific regulation of FRYL by mutating the three miR-1205 binding sites within
the 3’UTR of FRYL in all PCa cell line models.
To further examine this observation, RNA pulldown assays were performed to assess the
binding of miR-1205 to FRYL mRNA by transfecting a selection of cell lines modelling different
stages of PCa with either a biotinylated miR-1205 duplex or scramble biotinylated duplex for 24
hours. We used RWPE-1 (non-tumorigenic prostate epithelial cells), PC-3 (NEPC), MDA PCa 2b
(metastatic PCa) and C4-2B (CRPC) cells. We observed a moderate increase in FRYL pulleddown with biotinylated miR-1205 was observed in RWPE-1, MDA PCa 2b, and C4-2B cells (Fig.
3.6B). Significant enrichment of FRYL was observed in PC-3 cells transfected with the
biotinylated duplex, suggesting that miR-1205 directly binds to FRYL mRNA and this may be a
mechanism selected for in NEPC.
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Figure 3.6: miR-1205 regulates FRYL by the 3’UTR. C4-2B and PC-3 cells were co-transfected with
Genecopoeia pEZX-MT06 miRNA reporter empty vector or FRYL plasmid with a non-targeting negative
control or miR-1205 mimic for 24 hours. The Fluc and Rluc activity was measured. Luciferase activity is
normalized to the negative control luciferase activity. *P<0.05 compared to Negative control/FRYL Vector
(n=3). (a) C4-2B cells transfected with miR-1205 and the 3’UTR of FRYL in a luciferase expressing vector
revealed a significant decrease in luciferase activity when compared to control cells, indicating regulation
of FRYL through the 3’UTR. (b) Overview of RNA pull down assay is shown. A significant enrichment of
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FRYL was observed in PC-3 cells transfected with the biotinylated miR-1205 duplex (NB1205). *p<0.05
compared to Scramble Biotinylated Duplex (n=3). Data is presented as mean and bars represent standard
error of the mean +/- SD.
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Figure 3.7. Illustration of the direct binding of miR-1205 to FRYL. (a) Representation of the three miR1205 binding sites to FRYL 3-UTR. Matches were taken from TargetScanHuman. (b) LNCaP cells were
co-transfected with Genecopoeia pEZX-MT06 miRNA reporter empty vector or FRYL plasmid with a nontargeting negative control, miR-1205 mimic or miR-1205 mutant (containing a three nucleotide change
within the seed region: 5’ UGC 3’ to 5’ CUG 3’ for 24 hours. The Fluc and Rluc activity was measured.
Luciferase activity is normalized to the negative control luciferase activity. *P<0.05 compared to Negative
control/FRYL Vector. Data is represented as mean +/- SD.
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Discussion
The 8q24.21 chromosomal region was among the first cancer susceptibility loci identified
in early GWAS studies and became a hotspot for genetic polymorphisms that are associated with
diseases such as cancer, type II diabetes and end stage renal disease113. The region gained further
interest due to the presence of the MYC oncogene, which is dysregulated in more than 50% of
human cancers114. Further investigation into the 8q24 chromosomal locus revealed that this region
is sparse of protein-coding genes and contain mostly non-protein coding genes. As the
understanding of long non-coding RNAs improved over the years, there was a renewed interest in
discovering the functions of non-protein coding regions along the genome, including the 8q24
chromosomal region. PVT1 is one of the twelve long non-coding RNAs within the 8q24
chromosomal region that gained interest due to its interaction and stabilization with c-MYC and
functional roles that contribute to progression of cancer. Further investigation into the PVT1 locus
led to the discovery of six miRNAs including miR-1204, -1205, -1206, -1207-3p, -1207-5p, and 1208 encoded within this region. Functional studies on the PVT1-encoded miRNAs are very
limited and few functions have been identified to date. Further investigations into PVT1-encoded
miRNAs could facilitate discoveries into the function of the PVT1 locus in cancer and indicate the
role of long non-coding RNAs and miRNAs as novel targets in cancer therapeutics.
PVT1-encoded miRNAs have been linked to multiple cancers, including miR-1204 and
miR-1207-3p. The most well studied PVT1-encoded miRNA is miR-1204, which shares the same
promoter as PVT1 and is expressed upon activation by p53 and cAMP responsive element binding
protein 1 (CREB1) binding60,115. Additionally, our laboratory discovered that PVT1-encoded miR1207-3p is significantly underexpressed in PCa tissues and cell lines and indirectly regulates the
androgen receptor, indicating that miR-1207-3p could be an important regulator in PCa116,117.
Altogether, there are very limited studies on the characterization of other PVT1 encoded miRNAs
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especially including miRs-1205, -1206, -1207-5p, and -1208. To contribute knowledge on PVT1
encoded miRNAs, this study demonstrates novel findings into the molecular mechanisms of miR1205 in PCa.
It was previously reported that miR-1205 is expressed at very low levels among cancer cell
lines (not including PCa cell lines), suggesting a role in tumorigenesis 49,59. First, to determine the
expression pattern of miR-1205 in disease versus non-disease background, we analyzed miR-1205
expression in a cohort of tissues including normal, benign and PCa tissues. We discovered that the
mature miR-1205 transcript was underexpressed in PCa tissue when compared to normal prostatic
tissue. This underexpression was further observed among a panel of PCa cell lines when compared
to normal prostate epithelial cells. These observations suggested that loss of mature miR-1205 may
be occurring during PCa tumorigenesis, further linking 8q24 to PCa susceptibility. When miR1205 expression was examined in online consortiums containing TCGA sequenced cohorts,
amplification of miR-1205 was observed in PCa. Moreover, our lab observed a high copy-number
of PVT1 long non-coding RNA transcripts that contain exon 4A in PCa cells, when compared to
non-tumorigenic RWPE-1 cells118. However, while amplification and subsequent copy number
increase may occur at the locus for PVT1-encoded miRNAs, downstream regulation of miRNA
biogenesis should be examined. It was recently discovered that PVT1-encoded miRNAs do not
share the same promoters and may be subjected to differential regulation119. An additional study
examining small RNA deep sequencing and Cap Analysis Gene Expression (CAGE) profiling of
primary miRNAs further validated that miR-1205, miR-1206, miR-1207, and miR-1208 do not
share the same promoter as PVT1/miR-1204120. These findings corroborate with observed
PVT1/miR-1204 overexpression in cancers (regulated by the same promoter) and miR-1207-3p
and miR-1205 underexpression in PCa models (regulated by a different promoter within host gene)
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60,113

. In addition, this raises the question on whether PVT1 encoded miRNAs are characterized as

mirtrons (intronic miRNA spliced from primary RNA transcripts bypassing drosha cleavage) or as
intergenic miRNAs (transcribed by independent transcription units from host gene)64. Moreover,
as miR-1205 was shown to be amplified in PCa, a closer examination into the regulation at the
promoter region of miR-1205 will further reveal how miR-1205 expression is controlled that could
lead to a decrease in miR-1205 mature transcripts as observed in this study. For example, Li, et.al
demonstrated that the E2F1 transcription factor binds to the promoter of miR-1205 and represses
miR-1205 expression in laryngeal squamous cell carcinoma cells, indicating that the
transcriptional control on the promoter should be further examined to determine loss of miR-1205
mature transcripts observed cancer cells66. Additionally, with the increased interest in RNA
epigenetics, there has been investigations into the role of RNA methyltransferases in miRNA
biogenesis. RNA methyltransferases are important for the methylation of primary miRNA,
allowing for recognition and processing by DGCR8 during miRNA biogenesis 121. Loss of certain
methyltransferases can lead to reduced binding of primary miRNAs to DGCR8 resulting in
cessation of mature miRNA. Further studies into the origins and regulation of PVT1-encoded
miRNA, biogensis could reveal insight on how miRNAs could be underexpressed in cancers.
Nevertheless, we demonstrate for the first time that mature miR-1205 transcript is lower in PCa
cells and that it’s loss may contribute to cancer progression.
There is now an abundance of evidence indicating that miRNAs can function as tumor
suppressors and/or oncogenes, ultimately enhancing the progression of tumorigenesis. MiRNAs
are small molecules that can be found in biological fluids, such as urine and blood, whereby their
detection and quantification of their expression levels can be used as biomarkers to link cancer
incidence and progression. Moreover, with a proper delivery system, miRNAs can be used as
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inhibitors or mimics via anti-miR technology or replacement therapies, respectively, to treat
cancers

122,123

. As such, we were interested in discovering the role of miR-1205 in PCa tumor

progression and subsequently demonstrate its potential use as a novel therapeutic for aggressive
PCa. Previously observations indicate that miR-1205 has tumor suppressive properties in laryngeal
squamous cell carcinoma and non-small cell lung cancer in vivo models66,104. In this study, we
examine whether miR-1205 may have tumor suppressive properties in PCa. We present the
development of a novel tool and demonstrate its use for in vitro and in vivo techniques. A
biotinylated synthetic analog of miR-1205 (NB1205) and a control biotinylated synthetic scramble
duplex (NB1) was generated in effort to test our hypothesis that miR-1205 is a tumor suppressor.
Using this tool, we first showed that while miR-1205 does not regulate cell proliferation, it
moderately induces apoptosis through PARP cleavage, specifically in CRPC cells (Fig. 3.2B). It
would be important to further examine if increased concentrations of miR-1205 mimics would
increase apoptosis subsequently leading to loss of proliferation in CRPC cells and further examine
why it may be a selective mechanism in CRPC cells. Furthermore, our preliminary data indicate
that NB1205 suppressed tumors in an in vivo CRPC model (Fig. 3.3). Future studies should include
an increase in sample size and longer duration of treatment with NB1205 to further address the
role of miR-1205 in tumor suppression by inducing apoptosis of aggressive PCa cells, including
CRPC. Further exploration into the mechanisms of action that result in the tumor suppressive
abilities of miR-1205 could lead to a novel development of miRNA replacement therapies.
miRNAs comprise about 1-5% of the human genome

yet regulates about 30% of protein

coding genes 62,63. These small non-coding RNAs mediate mRNA gene silencing through RNAinterfering (RNAi) pathways. Partial binding to the 3’UTR of an mRNA results in translational
inhibition, whereas extensive binding to a target mRNA results in degradation. Moreover, each
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miRNA can have an average of 200 mRNA targets, illustrating their importance in regulating
multiple cellular processes

69

. We were interested in the mechanisms involved in the tumor

suppressor role of miR-1205 and therefore we examined the putative targets of miR-1205. FRYL
was identified using miRNA target prediction databases and validated as a target of miR-1205 in
PC-3 cells (NEPC), C4-2B (CRPC) and LNCaP (androgen-sensitive PCa) cells through luciferase
(Fig. 3.6). In humans, there are two related fry genes called furry (fry) and Fry-like (FRYL). FRYL
was first identified as a novel fusion partner of the mixed lineage leukemia (MLL) gene that was
reported in patients who developed treatment-related acute lymphoblastic leukemia (ALL)109,110.
The MLL gene has over 35 partner genes, which produce chimeric proteins containing the Nterminus of MLL and C-terminus of its fusion partner gene, such as FRYL. Moreover, it was
discovered that the C-terminus of FRYL contains leucine-zipper motifs and has transcriptional
activation properties, indicating that FRYL is a transcription factor. To further elucidate the role
of FRYL, we examined FRYL as a target of miR-1205 in PCa. We established for the first time
the overexpression of FRYL mRNA in CRPC and NEPC tissue when compared to normal or
benign tissue samples from WCM repository (Fig. 3.4), further supporting the idea that FRYL may
be involved in tumor-promoting mechanisms in cancers, such as PCa and MLL110. As a target of
miR-1205, we validated that miR-1205 binds to FRYL mRNA through RNA pull down analysis
and miR-1205 may modulate FRYL expression through regulation of 3’UTR mRNA as observed
in the luciferase activity assay (Fig. 3.7). Furthermore, we demonstrated that overexpression of
miR-1205 leads to loss of FRYL protein expression, indicating that miR-1205 could represses
FRYL. Ultimately, we demonstrated that FRYL can be regulated by miR-1205 in a regulatory
pathway in PCa. Further investigation into the putative oncogenic functionality of the Fryl protein
could reveal insight on the role of FRYL in PCa.

47

In conclusion, this chapter explores the putative functions of miR-1205 as a tumor
suppressor in different PCa models and identifies FRYL as a target and potential regulator of PCa
progression in some cellular backgrounds. Upon observing an underexpression of mature miR1205 expression in PCa cells and tissues (Fig. 3.1), further studies on miR-1205 biogenesis
regulation could reveal insight on the mechanisms that lead to low detection of mature miR-1205
in PCa. Moreover, as FRYL mRNA is overexpressed in PCa (Fig. 3.4 and 3.5), further examination
into the functions of FRYL could indicate a novel role in PCa.
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Chapter 4:
The role of microRNA-1205 in neuroendocrine differentiation of prostate cancer cells
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Introduction
Although the androgen receptor (AR) is not the only driver of prostate carcinogenesis,
almost 80-90% of PCa) are dependent on androgenic activity via AR signaling

12

. Therefore,

androgen deprivation therapy is critical for patients that display indications of high-risk localized
or metastatic PCa and is currently the most effective treatment that significantly improves survival
rates 3-5. However, 10-20% of patients develop castration resistant PCa (CRPC) due to failure of
tumor regression upon treatment, in which 33% with CRPC develop metastatic CRPC (mCRPC)
within two years of diagnosis

6-8

. While several next generation hormone treatments, such as

abiraterone acetate and enzalutamide, enhance survival rates for men diagnosed with mCRPC,
approximately 20-40% of patients do not respond to treatments and those who initially respond to
treatments may acquire secondary resistance

9,10

. Moreover, as PCa is a very heterogeneous

disease, some patients also acquire rare PCa subtypes after ADT relapse, including

NEPC

,

that are characterized as AR-negative and survive with complete independence of AR signaling.
Some of this heterogeneity is evident in the data presented in Chapter 3 using different tissues and
cell models. More recently, NEPC has been observed in 15-20% of patients with prostate
adenocarcinoma who received chemotherapy, including treatments with abiraterone and
enzalutamide 124. The transformation from prostate adenocarcinoma to NEPC as a consequence of
androgen deprivation therapies is clinically termed treatment-related NEPC (t-NEPC)

40-43

.

Although NEPC is rare (<2% incidence in the United States), men who develop NEPC or t-NEPC
have very poor prognosis due to the lack of targeted therapies and the limited identification of
biomarkers 38. Resistance towards ADTs creates a new challenge for treating men with CRPC and
better understanding of these mechanisms will provide knowledge on how to address PCa
heterogeneity.
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Genome wide association studies (GWAS) has identified hundreds of genetic variants
associated with high risk for developing PCa44. The 8q24 chromosomal region was one of the first
regions to be identified and is considered to be the most important PCa susceptibility locus 45. This
region is commonly known to be a “gene desert” due to the lack of protein coding genes

46,47

.

Within the 8q24 chromosomal region lies the PVT1 gene, which encodes a series of non-protein
coding alternatively spliced transcripts along with a cluster of miRNAs (-1204, -1205, -1206, 1207-5p, -1207-3p, and -1208) 48,49,51. PVT1 is amplified and overexpressed in many cancers and
has been reported to function as a miRNA sponge ultimately inducing proliferation and
suppressing apoptosis in cancer cells 52-56,101. Moreover, our lab and others have demonstrated the
potential role of PVT1 as a biomarker in aggressive PCa, non-small cell lung cancer and
osteosarcoma
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{Traversa, 2021 #212}. However, the importance of PVT1-encoded miRNAs is

largely understudied. Recent reports have shown the implications of miR-1204 in the suppression
tumor growth, suggesting a role in oncogenesis

59,60

. Furthermore, our lab has established the

potential clinical significance of miR-1207-3p as a biomarker and putative therapeutic option via
a novel regulatory pathway in PCa61. A more in-depth investigation of PVT1-encoded miRNAs
will further demonstrate the importance of the 8q24 chromosomal locus in PCa.
Due to the increasing evidence of PVT1-encoded miRNAs in cancer, we were interested
in elucidating the role of miR-1205 in cancer. In chapter 3, we observed that miR-1205 is
underexpressed PCa cells and tissues. Additionally, our preliminary data suggests that miR-1205
has tumor suppressive properties and induces apoptosis of CRPC-PCa cells (C4-2B) through
PARP1 cleavage (Fig. 3.2). This chapter aims to further define the molecular signature of miR1205 and its role in biological mechanisms and molecular functions by identifying and
characterizing the targets of miR-1205. In chapter 3, we characterized the function of miR-1205
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by validating the direct binding to FRYL mRNA as a molecular target, leading to either mRNA
instability or translational repression of FRYL. As previously mentioned, human FRYL and fry
are very similar in structural domains, suggesting they may have similar functions including
putative roles in dendritic branching, spindle formation during mitosis and transcriptional
control111. Although there are certain motifs that can predict the functions of FRYL protein, such
as the leucine zipper motif and its role in transcriptional control, there are no other distinctive
functional domains or motifs, which creates difficulty for predicting functions of FRYL. Gene
Ontology analysis predicts that FRYL may be involved in cell morphogenesis and neuron
projection development. Therefore, as a target of miR-1205, the aim of this chapter will also
explore how miR-1205 and FRYL could regulate neuroendocrine differentiation of PCa cells.
Results
4.1. Identification of miR-1205 targets
To further understand the role of miR-1205 in PCa, we sought to identify the direct
molecular targets of miR-1205 in prostate models of normal epithelial (RWPE-1), metastatic PCa
(MDA PCa 2b), androgen insensitive (C4-2B), and androgen negative (PC-3) cells by performing
a RNA pulldown. Cells were transfected with either scramble or miR-1205 biotinylated duplexes
and downstream mRNA targets were captured using streptavidin-conjugated beads. Total RNA
was extracted and sequenced. Annotated peaks of miR-1205 mRNA targets were compared
between RWPE-1, MDa PCa 2b, C4-2B and PC-3 cells with a Venn Diagram analysis (Figure
4.1). Interestingly, we identified 3,981 mRNA targets exclusive to non-tumorigenic RWPE-1
prostate epithelial cells when compared to mRNA targets among PCa cell lines, indicating a novel
pool of miR-1205 mRNA targets in normal regulatory functions of epithelial prostate cell
maintenance. Altogether, 988 miR-1205 mRNA targets were shared between prostate models. A
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smaller fraction of targets identified were exclusive toward each PCa cell model, indicating
existence of novel targets among different disease stages. Interestingly, the top five of the 988
common targets identified among all cell lines were matched to mRNA targets in miRNA
prediction databases, such as TargetScan and miRDB, suggesting that these genes could be
common miR-1205 targets whose miRNA recognition sites are not altered between normal or
disease backgrounds. Lastly, FRYL, the miR-1205 target previously identified (Figs. 3.4-3.7
was also detected as a miR-1205 target in all four cell lines.

),

When NB1205 is overexpressed,

FRYL mRNA binding is enriched in vitro. Our data indicates that miR-1205 has over 2,000 targets
in each cell line, however, miRNAs have an average of ~300 targets and therefore two or more
RNA pulldown technical replicates in each cell line should be sequenced to eliminate target bias
and enrich for specific miR-1205 targets.
4.2. Characterization of miR-1205 targets
CHIP-seeker was additionally used to determine the genomic feature distribution of RNAseq peaks along the human genome. Approximately 50% of miR-1205 mRNA targets in RWPE1, PC-3, and MDA PCa 2b cells contained target sequences enriched at the 3’UTR (Figure 4.2).
Interestingly, the distribution of peaks in C4-2B cells were more dispersed with approximately
38% peak enrichment at the 3’UTR, 12% within exons, 12% within the 1st intron and 25% among
other introns, suggesting a higher content of mutated genes. Similar to the data presented here, it
has been reported that C4-2B cells have over 3,000 mutated genes when compared to androgensensitive LNCaP cells, suggesting the existence of potential novel miRNA response elements
across the genome in aggressive resistant PCa cells125.
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Figure 4.1: RNA pulldown analysis and sequencing of miR-1205 targets. RWPE-1, PC-3, MDA PCa 2b
and C4-2B cells were either transfected with a biotinylated miR-1205 duplex or non-targeting scramble
control duplex. MiR-1205 mRNA targets were sequenced and aligned to hg38 reference genome by
Arraystar INC. CHIP-seeker was used to annotated peaks of enriched miR-1205 targets performed by Dr.
Dennis Huang and Konstantinos Krampis. The representative figure illustrates a Venn diagram analysis of
differentially expressed genes across four comparisons of mRNA targets in RWPE-1, PC-3, MDA PCa 2b
and C4-2B cells and the overlap between each set of genes. Represented are the top five most enriched
targets in RWPE-1 (n=3016), PC-3 (n=796), MDA PCa 2b (n=181), C4-2B (n=518) and all four cell lines
(n=988).
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Figure 4.2: Distribution of RNA-seq peaks along human annotated genomic features. Molecular targets of
miR-1205 were isolated through RNA pulldown assay and sequenced. CHIP-seeker was used to annotate
peaks of miR-1205 targets and define miR-1205-mRNA binding on different regions within the gene
targets. Among the reads matching the human genome, almost 50% of miR-1205 mRNA targets were
enriched along the 3’UTR in RWPE-1, PC-3 and MDA PCa 2b cells. In C4-2B cells, miR-1205 targets
were additionally enriched at the 3’UTR, however, an increase of enrich along the introns and exons of
mRNA targets were observed, indicating novel response elements among miR-1205 target genes.
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Next, gene ontology enrichment analysis was performed using The Gene Ontology
Consortium’s online database (http://www.geneontology.org/). The 988 genes enriched among all
four cell lines were included into the enrichment analysis. Fold enrichment (number of genes in
set/expected number of genes) and significant gene enrichment for each category was determined
(Fig. 4.3). The top biological process for miR-1205 mRNA targets was cerebellar neuron
development and included CRK, CRKL, and NANOS1. The top molecular process for enriched
miR-1205 targets was protein kinase binding and contained over 40 targets in this category, with
the most notable target as PARP1.
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Figure 4.3: Gene ontology analysis of 988 miR-1205 enriched target genes across four in vitro prostate
models. (a) The top 20 GO terms for biological function of miR-1205 targets were determined using gene
ontology analysis and were ranked by fold enrichment. GO analysis of miR-1205 targets were greatly
associated with cerebellar neuron development pathways, indicating a novel mechanism putatively
regulated by miR-1205. (b) Similarly, the top 15 GO terms for molecular function of miR-1205 targets
were determined using gene ontology analysis and ranked by fold enrichment. GO analysis of molecular
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functions of miR-1205 targets revealed involvement in various functions including, protein kinase activity,
protein-protein domain specific binding, and RNA binding properties.
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4.3. miR-1205 regulation of FRYL mRNA may play a role in PCa NED development
As mentioned in chapter 3, FRYL is predicted to play a regulatory role in dendritic
branching, similar to the homolog-like fry protein, indicating that FRYL could play a role in
maintaining neuronal-like structures

126

. As the morphology of neuroendocrine cells is very

distinct, in which dendrite-like protrusions are observed, this initiated our hypothesis that FRYL
may play a role in the progression of PCa NED, a resulting mechanism due to ADT
resistance127,128. Moreover, previous publications indicate that miR-1205 may play a role in
cellular differentiation and regulation of pluripotency of stem cells, indicating that miR-1205 could
potentially acquire a molecular signature of NED. To test these hypotheses, we first induced NED
in vitro and assessed the expression levels of miR-1205 and FRYL mRNA. NED was induced by
culturing LNCaP cells in RPMI-1640 medium supplemented with 10% charcoal-stripped FBS
(androgen deprivation conditions). Cells were maintained in these conditions for fourteen days and
expression levels of miR-1205, FRYL and NED markers (chromogranin A and NSE) were
examined through by RT-qPCR and Western blotting and morphological changes were observed
through light microscopy (Fig. 4.4A). After LNCaP-NED was induced, we observed an
upregulation of FRYL mRNA expression whereas miR-1205 was significantly downregulated
when compared to undifferentiated LNCaP cells (Fig. 4.4A), indicating a putative role of miR1205 regulation of FRYL in PCa NED.
To determine whether the miR-1205/FRYL regulatory pathway is important in PCa NED,
miR-1205 was exogenously overexpressed using a miR-1205 mimic (NB1205) as in Fig. 3.5-3.7,
and neuroendocrine marker expression was subsequently assessed through Western blotting
analysis. When miR-1205 mimic, NB1205, was transfected into LNCaP cells, we observed a
downregulation of neuroendocrine markers NSE and Aurora A when compared to LNCaP cells
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transfected with NB1 (scramble oligonucleotide) (Fig. 4.4B). This observation suggests that miR1205 may be involved in NED. We additionally determined through our RNA pulldown-RNA seq
study (Fig. 4.1) that miR-1205 does not directly bind to Aurora A or NSE, suggesting that miR1205 may induce NED by an indirect mechanism that may regulate Aurora A or NSE expression.
To determine whether miR-1205 regulation of FRYL is involved in NED and de-differentiation of
NEPC cells, FRYL was silenced in PC-3 small cell prostatic carcinoma cells, a model of NEPC.
Interestingly, we observed no changes in NSE expression and only a 20% decrease in Aurora A
expression, suggesting that miR-1205 regulation of FRYL may not significantly regulate NED in
PCa cells (Fig. 4.4C).
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Figure 4.4: miR-1205 regulation of FRYL mRNA may play a role in PCa NED development. (a)
Morphology and NED marker expression (left) and miR-1205 and FRYL mRNA levels (right) of LNCaP
cells after inducing NED by culturing androgen-sensitive LNCaP cells under androgen deprivation
conditions. Data is presented as mean and bars represent mean +/- SD. (b) A negative control scramble
oligonuceltide (NB1) and miR-1205 mimic (NB1205) were transfected in LNCaP cells to assess induction
of NED in androgen-sensitive cells. MiR-1205 overexpression led to a decrease in neuroendocrine markers,
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NSE and Aurora A protein expression (c) NSE and Aurora A levels after siRNA-mediated silencing of
FRYL in PC-3 cells.
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Discussion
Prior to this study, miR-1205, -1206, -1207-5p and -1208 were the most understudied
PVT1-encoded miRNAs. As time progressed, the significance of miRNA regulation in various
cell processes were being elucidated and stringently explored as putative therapeutics, which led
to an increased interest in understanding the functional role of miRNAs in disease progression.
Early functional studies on miR-1205 function emerged as a “sponging” target of circular RNAs
and as a tumor suppressor in glioma, osteosarcoma, ovarian cancer, non-small cell lung cancer and
laryngeal squamous cell carcinoma66,104,129-134. The goal of this study was to examine the role of
miR-1205 in a PCa model due to its location within 8q24 chromosomal region, also known as the
most important PCa susceptibility locus. Prior investigations on the function of miR-1205 were
hypothesized by examining predicted molecular targets in databases such as miRDB and
TargetScan, which revealed putative roles in Ras signaling pathways and regulating pluripotency
of stem cells104. Herein, we elucidated the function of miR-1205 in PCa by sequencing and
identifying the binding molecular targets of miR-1205 among different models of PCa disease. We
demonstrated that by performing an RNA pull-down and isolating the binding targets of miR1205, we can differentiate between targets that are exclusive to disease stages and targets that may
be common on a more global scale in regulating various cellular functions. Establishing miRNA
signatures can exploit the regulation of miRNA molecular targets on activating putative oncogenic
pathways and thus create new advancements for well elucidated targeted therapeutics.
To understand the role of miR-1205 in cellular and molecular functions, we isolated and
sequenced (via ArrayStar INC and analyzed in collaboration with Dennis Huang and Dr.
Konstantinos Krampis) miR-1205 targets and characterized the biological and molecular processes
regulated by miR-1205. RNA pulldown of miR-1205 targets were sequenced and enriched
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annotated peaks were examined for genomic and functional analysis in normal (RWPE-1),
metastatic (MDA PCa 2b), castration-resistant (C4-2B) and androgen-negative/NEPC (PC-3)
models. We first differentiated miR-1205 targets among all PCa cell line models and observed that
normal prostate epithelial cells contained the greatest exclusivity of miR-1205 targets when
compared to the PCa cancer cell line models. This generally represents the shift in mRNA target
recognition sites in normal versus disease models, indicating the increase in chromosomal
aberrations in cancers and therefore the generation of novel targets exclusive in diseased
environments. Interestingly, NOTCH2NLA (Notch Homolog 2 N-Terminal-Like Protein A) and
NOTCH2NLB (Notch Homolog 2 N-Terminal-Like Protein B) were identified as one of the most
enriched mRNA targets of miR-1205 in PC-3 cells, a model of androgen-negative PCa/NEPC.
NOTCH2NLA and NOTCH2NLB evolved from the NOTCH2NL gene through gene duplication
of the NOTCH2 gene and physically interact and enhance activation of NOTCH1-3135. The
functional importance of the NOTCH gene was initially discovered in Drosophila melanogaster
and revealed the significance of the notch signaling pathways in cell-fate determination,
proliferation, and differentiation136. Notch signaling pathways are evolutionarily conserved and
required for prostate development. Dysregulation of notch signaling have been linked to many
neoplasms including PCa and was observed to increase with high grade PCas137. Therefore, it is
interesting to reveal NOTCH2NLA and NOTCH2NLB as targets of miR-1205 in low miR-1205
expressing PC-3 cells, which was not detected in RWPE-1, C4-2B, or MDA PCa 2b cells. Further
analysis into how the expression of NOTCH2NLA and NOTCH2NLB in PCa could implicate a
novel NOTCH-related pathway regulated by PVT1-encoded miR-1205.
To further examine the functional role of miR-1205, we examined the distribution of
enriched peaks of miR-1205 target sequences along the features of the genome. We discovered

64

that miR-1205 molecular targets in RWPE-1, MDA PCa 2b, and PC-3 cells are aligned to
annotated 3’UTRs, representing the canonical binding sites for miRNAs on target genes. However,
the genomic distribution miR-1205 binding elements in C4-2B cells were more dispersed across
the genome, including not only binding sites within the 3’UTR, but also within exons and introns
of mRNA targets. Dysregulation of genes that encode proteins associated with splicing machinery
are often observed in aggressive PCas138. Recent reports indicate that various splicing factors are
highly expressed and upregulated in CRPC tissues139,140. The upregulation of spliceosome factors
are hypothesized to be the cause of the emergence of androgen receptor variants, such as AR-V7,
that lead to the progression and maintenance of CRPC. Furthermore, upregulation of splicing
machinery could lead to gene diversity, such as intron retention, generating novel miRNA response
elements along the genome. A recent report discovered that increased splicing dysregulation
correlates with disease aggressiveness and established intron retention as a hallmark of aggressive
PCa141. Thus, the increase in miRNA binding sites among intronic regions in C4-2B cells (CRPC
model) could be the result of increased intron retention. Moreover, SNPs that may associate with
CRPC and located within miRNA binding sites could also differentiate between binding sites
among the 3’UTR, exons and introns of mRNA targets142. Lastly, we performed gene ontology
analysis to characterize functional and molecular pathways regulated by miR-1205. Interestingly,
we discovered that miR-1205 targets are mostly associated with cerebellar neuron development
and targets of miR-1205 bind to various macromolecules including protein kinases, protein
specific domains, RNA and DNA. The discovery of miR-1205 involvement in cerebellar
development is the first among the PVT1-encoded miRNAs to be linked a neuronal differentiation
pathway, with associated targets CRK, CRKL, and NANOS1. CRK and CRKL are adaptor
proteins that transduce signaling pathways and regulate many biological phenomena including cell
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proliferation, differentiation and movement143,144. Interestingly, it was previously demonstrated
that miR-1205 directly binds to CRKL mRNA in colon cancer cells145. The authors revealed that
CRKL is overexpressed in human colorectal cancer tissues and inhibition of CRKL suppressed
proliferation, migration and invasion of colon cancer cells, suggesting that CRKL acts as a tumor
promoter in colorectal cancer. To this end, CRK and CRKL along with NOTCH2NLA and
NOTCH2NLB could be investigated in vitro and in vivo in future studies to further link miR-1205
to cellular differentiation and thus portray a putative signature for biological processes involved in
cancer.
Amplification and overexpression of MYCN and AURKA genes have been observed in
confirmed t-NEPC tissue, and both induce a neuroendocrine cell phenotype in prostatic
adenocarcinoma cells through transcriptional reprogramming mechanisms39,146,147. This
mechanism, described as

NED , is thought to occur as a means for survival against ADTs due

to the lack of AR expression and dependence on AR signaling for survival among neuroendocrine
cells. In addition to NED, it is hypothesized that NEPC cell population can also increase due to
PCa stem cells that are increasingly differentiating into neuroendocrine cells. It is not clear whether
NEPC cells increase via cancer stem cells and/or transdifferentiation in aggressive disease. This
field requires further understanding as more men are diagnosed with PCa and therefore, develop
resistant and untreatable cancers. Whether the origins of neuroendocrine cells within a PCa tumor
emerge from PCa stem cells or through cellular reprogramming mechanisms, novel findings into
the mechanisms that drive NEPC will not only help create new therapies for treatment, but also to
shed some light on the role of neuroendocrine cells within the prostate.
As miR-1205 was previously predicted to play a role in cell differentiation and suggested
to regulate various conserved signaling pathways including regulating pluripotency of stem cells,
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we sought to understand the role of miR-1205 in NED through previously validated target, FRYL
in PCa59,104. The human genome contains two fry-related genes including fry and FRYL, which
share almost identical amino acid compositions among conserved domains

148

. Fry has been

studied in multiple models such as, Drosophila melanogaster, and plays a crucial role in multiple
cellular processes including, dendritic branching during development, morphogenesis, cell
division and cell polarization, however, it is unknown whether the FRYL protein shares these
functions126. Neuroendocrine cells located within the prostate epithelium have features of dendritelike morphologies, which further encouraged investigation into the role of miR-1205 and FRYL
in NED induced by androgen deprivation128,149-151.
To examine the role of miR-1205 and FRYL in NED, we cultured LNCaP androgensensitive cells under androgen deprivation conditions to develop an in vitro PCa-NED model. In
LNCaP-NED cells, we observed a significant decrease in miR-1205 expression and an increase in
FRYL mRNA expression when compared to undifferentiated LNCaP cells, indicating that miR1205 regulation of FRYL may be involved in NED in aggressive PCa. Moreover, in chapter 3 we
observed that FRYL mRNA expression was higher in PCa tissue, and more significantly in CRPC
and NEPC patient tumor samples, when compared to prostate benign tumors further implicating
that FRYL could drive NED. To test this hypothesis, we overexpressed miR-1205 in LNCaP cells
and examined changes in NED marker expression. Our data showed that overexpression of miR1205 in androgen sensitive cells led to an upregulation of neuroendocrine markers (NSE and
AurA) and FRYL suggesting that miR-1205 regulation of FRYL may be involved in NED (Fig.
4.4B). To determine if FRYL can directly regulate NED and de-differentiate NEPC cells, siRNAmediated knockdown of FRYL was performed in PC-3 cells, which models NEPC. Interestingly,
loss of FRYL protein did not induce changes in NSE expression and only reduced in AurA
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expression by about 20%, indicating that miR-1205 may not be regulating NED through FRYL
regulation in PC-3 cells (Fig. 4.4C). Although fry and FRYL may have similar motifs and
functional domains, the data indicates that they may be involved in different mechanisms. It would
be interesting to observe whether miR-1205 regulation of FRYL in NED may have an effect on
NED in vivo or using a 3D in vitro organoid NEPC model. Ultimately, our data suggests that miR1205 regulates NED indirectly and therefore, further investigation into miR-1205 targets may
uncover novel mechanisms that drive NED.
In conclusion, we discovered a putative miR-1205 signature in cerebellar neuronal
differentiation through CRK, CRKL, and NANOS1. Further studies on the potential pathways
regulated by miR-1205 in normal prostate epithelial functions, metastatic PCa, CRPC, and NEPC
should be explored with the exclusive and common miR-1205 targets identified. We also
discovered that while loss of miR-1205 may induce NED, a phenotype that appears in aggressive
PCa, the regulation of NED is independent of FRYL protein functions. Although FRYL may not
drive NED in PCa cells, which model NEPC, in an in vitro model, we observed that FRYL mRNA
is overexpressed in aggressive PCa tissues (CRPC and NEPC), suggesting importance in the
progression of aggressive disease. Further investigation of miR-1205 in NED and the role of FRYL
in PCa in vivo may reveal novel insights in PCa signaling pathways that drive aggressiveness.
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Chapter 5:
Conclusion, Significance and Future Directions
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Since the discovery of miRNAs in 1993 and the establishment of their involvement in
cancer nine years later, major discoveries have been made on their roles in normal and disease
cellular homeostasis152,153. It became evident that the tight control of miRNA expression and
specific recognition of target mRNAs demonstrated their potential to be used as cancer
therapeutics. However, prior to reaching the development and production stages of miRNA-based
therapies for humans, stringent investigation of their targetable molecular pathways must be
studied and assessed for their impact on tumor regression. Using this approach, the aim of this
dissertation was to examine the role of PVT1-encoded miR-1205 in PCa and identify putative
pathways that may be involved in normal and disease homeostasis. Based on quantitative and
qualitative analyses downstream of miR-1205 regulation, this work was among the first to discover
that miR-1205 is underexpressed in PCa. In chapter 3, our results suggest that miR-1205 may have
tumor suppressive properties in CRPC, an aggressive form of PCa, and characterized the binding
to target FRYL mRNA. In chapter 4, we characterized a putative miRNA signature for miR-1205
and concluded that miR-1205 could potentially regulate neural differentiation pathways in a
subtype of aggressive PCa (NEPC). Altogether, the results of this work provide novel findings on
the role of miR-1205 in cell and cancer biology, further indicating the importance of miRNAs
located within 8q24 chromosomal locus in PCa.
Chapter 3 presents rationale for investigating the non-coding components along the 8q24
chromosomal locus. The discovery of MYC and emergence of its role as an important oncogene
in a variety of cancers led to the investigation of its regulation and surrounding location. In 2006,
a GWAS study identified multiple SNPs associated with PCa risk along 8q24 chromosomal locus,
which is the chromosomal location that hosts MYC94. Within the next five years, additional SNPs
were identified along this region and were reported to be associated with other types of cancers
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including breast, colon, ovarian, leukemia, bladder, esophageal and other diseases including type
I diabetes113. Although cancer associated SNPs were identified within the MYC locus, additional
SNPs were identified in regions of the 8q24 locus that are mostly void of any protein-coding genes,
indicating that these regions could have functional roles in cellular processes. As a result,
subsequent studies identified multiple non-protein coding RNAs that present functional roles in
cancer as long non-coding RNAs and miRNAs. Presently, numerous studies are still ongoing to
characterize the functions of these non-coding RNAs. The work discovered within this thesis
focuses on further establishing the importance of 8q24 by examining the role of miR-1205 in PCa,
which is located within the 8q24 chromosomal locus.
In chapter 3, we concluded that miR-1205 is underexpressed in PCa tissues and cells. The
underexpression of miR-1205 observed in these PCa models are reflective of the mature miR-1205
transcript, as determined using miRNA specific RT-qPCR analysis. This finding raises the
question of the upstream events that lead to the loss of mature miR-1205 transcripts in PCa. One
level of investigation should examine the transcriptional control on the promoter of miR-1205. A
recent publication examining the PVT1 promoter mapped six Transcription Start Sites (TSS) along
the PVT1 locus and discovered that the first two TSS’s act as tumor suppressors in vivo
independent of PVT1 long non-coding RNA functions and undergoes promoter-enhancer
competition with the MYC promoter119. Using CRISPRi, all six TSS were silenced to identify the
function of PVT1 in breast cancer cells. Interestingly, silencing of the most 5’ TSS’s of PVT1
increased breast cancer cell proliferation and in vivo tumor growth. When examining the effect of
the other TSS, including the TSS of the miR-1205 promoter, no change in proliferation of breast
cancer cells was observed. It would be interesting to investigate whether knockout of the miR1205 promoter could promote proliferation in PCa cells, which would further demonstrate its
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putative role as a tumor suppressor in PCa. Moreover, it would be interesting to examine the
enhancer sites of the miR-1205 promoter to define elements that may induce and repress
transcription of miR-1205. For example, it was demonstrated by Li, et.al that E2F1 transcription
factor binds to the promoter of miR-1205 and represses miR-1205 expression, revealing a putative
regulation unit on the miR-1205 promoter66. Lastly, intrinsic miRNA regulation of primary
miRNAs or pre-miRNAs through RNA editing and RNA methylation, respectively, should be
investigated67. In the first mechanism, RNA editing occurs when adenosine is converted to inosine
through activity of adenosine deaminases (ADARs). This editing can occur within the stem region
of a primary-miRNA, which can prevent Drosha binding, or inhibition of Dicer processing,
ultimately leading to the loss of mature miRNA transcript. In the second mechanism, RNA
methyltransferases can O-methylate the 5’ monophosphate of pre-miRNAs, interfering with Dicer
binding and thus Dicer-independent processing. In summary, mechanisms of upstream regulation
of miR-1205 could reveal novel insights on the underexpression of mature miR-1205 transcripts
observed in PCa.
Within the field of cancer biology, there is much evidence indicating that miRNAs can
function as tumor suppressors and/or oncogenes, ultimately enhancing the progression of
tumorigenesis. Furthermore, their potential role in cancer diagnosis, prognosis and treatments are
under rigorous investigation. miRNAs are small molecules that can be found in biological fluids,
such as urine and blood, in which their detection and expression levels can be linked to cancer
progression. Moreover, with a proper delivery system, miRNAs can be used as inhibitors or
mimics via anti-miR technology or replacement therapies, respectively, to treat cancers 122,123. In
chapter 3, our data suggests a putative role of miR-1205 as a tumor suppressor in aggressive PCa.
Analyzing a limited number of animals and with significant differences among the control, our

72

preliminary data suggest a decrease in tumor volume of CRPC xenografts when mice were injected
with a novel synthetic biotinylated miR-1205 duplex (NB1205). However, a more effective
delivery system could improve these putative tumor suppressive properties. While the biotin
modification on NB1205 increases the stability for delivery and cellular uptake, additional
modifications such as -Cy3 and even the use of lipid nanoparticles could be incorporated for better
efficiency in delivery and subsequent verification of delivery to tumor cells154,155. Moreover, a
higher sample size of mice should be used in the study for each treatment group to eliminate any
bias towards potential outliers. Additional studies have additionally demonstrated a potential
tumor suppressor role of miR-1205 in cancer. Li, et.al synthesized a miR-1205 lentiviral construct,
infected laryngeal cancer cells and implanted infected cells into mice66. They observed a notable
suppression of proliferation and decreasing tumor volumes and weights of mice when miR-1205
was overexpressed, suggesting tumor inhibition properties. Additionally, Yan, et.al demonstrated
that overexpression of miR-1205 using a mimic encapsulated in linear polyethylenimine
suppressed tumor growth in nude mice with xenografted human lung tumors104. Altogether, with
the work presented within this thesis and previous work, it is suggestive that miR-1205 has tumor
suppressor properties in cancer.
Lastly, in chapter 3 we examined a downstream pathway in which miR-1205 binds to its
target mRNAs and regulates its stability and/or translation. To determine targets that may be
involved in PCa progression we examined predicted targets of mRNA using miRNA prediction
databases and assessed for their expression in PCa. We then identified fry-like (FRYL) as a
potential target of miR-1205 and observed its significant mRNA overexpression in several samples
among three separate PCa tissue cohorts, when compared to benign prostate and/or normal tissue.
FRYL was initially identified as a partner on a fusion gene called MLL (mixed lineage leukemia),
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which encodes a histone methyltransferase found in a patient with treatment-related acute
lymphoblastic leukemia. The fusion protein is believed to select for the C-terminal domain of
FRYL due to its transcriptional activation properties. However, FRYL encodes a protein, whose
function is not well understood. Therefore, because miR-1205 is underexpressed and FRYL is
overexpressed in PCa, we were interested in whether miR-1205 can directly bind to FRYL mRNA
as a novel downstream pathway in PCa. We observed that miR-1205 has three putative binding
sites on the 3’UTR of FRYL and validated FRYL as a direct molecular target of miR-1205 by
performing RNA pulldown assays (Fig. 3.6). Using luciferase assays, we determined that miR1205 regulates Fryl expression by its 3’UTR (Figs. 3.6 and 3.7). Moreover, when miR-1205 was
overexpressed in PCa cells, FRYL protein expression decreased (Fig. 3.5), indicating that miR1205 is involved in regulation of FRYL expression. Altogether, we demonstrated that miR-1205
can regulate expression of its targets, including FRYL, by regulating either mRNA stability or
translation. Future studies can explore additional targets of miR-1205 and pathways involved in
this regulatory mechanism to further define the molecular signature of miR-1205 as a tumor
suppressor in PCa.
In effort to further investigate the functional role of FRYL, previous publications identified
a MLL and FRYL fusion protein that led to the discovery that the c-terminus of FRYL exhibits
transcriptional activation properties, indicating that FRYL is a transcriptional activator
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. In

support of this hypothesis, Yatim, et.al demonstrated that FRYL is required as a coactivator for
NOTCH1 transcriptional activity in human T cell acute lymphoblastic leukemia cells156.
Therefore, it will be interesting to investigate in future experiments the role of FRYL as a
transcription factor and its possibility to act as a fusion partner for genes involved in cancer
progression through chromatin-immunoprecipitation analysis. Moreover, previous evidence
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demonstrated that fry, the homolog-like of FRYL, aids Aurora kinase A mediated signaling during
mitosis. The fry protein is phosphorylated by the cyclin-dependent kinase 1 (Cdk1), which leads
to the binding of the Aurora A kinase at the C-terminal domain of fry. The interaction between fry
and Aurora A kinase occurs during early mitosis and serves as a scaffold at the spindle poles157.
To further examine the role of FRYL, the interaction between FRYL and Aurora kinase A could
be examined as putative complex that is important for cell cycle progression. Aberration of this
signaling pathway could lead to improper chromosomal segregation, thus contributing to
abnormalities often present in cancer cells.
In chapter 3, we validated that miR-1205 binds to FRYL (Fig. 3.6) and modulates the
expression of FRYL (Fig. 3.5) through the 3’UTR of FRYL mRNA (Figs. 3.6 and 3.7). In chapter
4, we sought to identify the molecular targets of miR-1205 in PCa to further define the role of
miR-1205. We identified the potential molecular signature for miR-1205 as a regulator of neuralassociated networks. Gene ontology analysis of the 988 mRNA targets enriched in four prostate
cell line models (RWPE-1, C4-2B, MDA PCa 2b and PC-3) indicated 25-fold enrichment of miR1205 target mRNAs overrepresented in cerebellar neuron development, with specific associated
targets: CRK, CRKL, and NANOS1.

The level of enrichment

indicates that 3 of the 988 miR-

1205 targets (CRK, CRKL, and NANOS1) are genes associated with the biological process:
cerebellar neuron development indicating that miR-1205 may regulate neuron development in the
cerebellum. Furthermore, we observed enrichment of NOTCH2 binding partners, NOTCH2NLA
and NOTCH2NLB, in PC-3 cells, which are also represented in cerebellar neuron development
mechanisms according to gene ontology analysis. When examining the gene ontology of miR1205 predicted targets in TargetScan, miRDB, and TargetMiner, we similarly observed fold
enrichment of reported miR-1205 mRNA targets in neural-associated pathways including,
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regulation of dendrite development, axon development, regulation of synapse development and
organization, and neuron/cell projection organization and assembly (Fig. 5.1). Altogether, we can
conclude that miR-1205 could play an important regulatory role in a variety of neural-associated
networks

and

future

work

into

the

investigation

of

miR-1205

in

neuron

development/differentiation should be performed using in vivo models to better understand the
number and nature of its targets.
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Figure 5.1: Gene ontology analysis of predicted miR-1205 target genes TargetScan, miRDB and
TargetMiner. Putative targets of miR-1205 were examined for their role in biological functions by
performing gene ontology analysis (http://geneontology.org/). Targets of miR-1205 predicted
from miRNA target prediction databases: TargetScan, miRDB, and TargetMiner, were used to
determine potential biological mechanisms regulated by miR-1205. Altogether, miR-1205 may
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regulate a variety of neural-associated pathways including, axon development, dendrite
development, and neuron/cell projection organization.
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Regulation of mature miR-1205 and subsequent loss of binding to its mRNA targets could
occur through interaction with a competitive-endogenous RNA (ceRNA) or “miRNA sponges”.
There are many reports suggesting the functional role of long non-coding RNAs binding and
sequestering miRNAs, leading to global decrease of the respective miRNA mRNA target
expression158-161. Interestingly, RNA pulldown analysis of miR-1205 binding targets in chapter 4
also revealed enrichment for long non-coding RNAs, suggesting that increase of miR-1205
molecular targets observed in PCa cells could either be induced by high expression of recognized
ceRNA leading to sequestering of miR-1205 (supporting ceRNA hypothesis) or by binding to a
miRNA response element on the transcript (miRNA targeting hypothesis). Further investigation
on the expression patterns of miR-1205 and putative ceRNA could reveal novel insights on ceRNA
regulation of miR-1205 or miR-1205 regulation of long non-coding RNAs. Moreover, future
experiments with RNA pulldowns and subsequent RNA sequencing of miR-1205 targets should
be examined in additional cancer models and with more technical replications included.
The initial evidence on the characterization of miR-1205 in molecular pathways were
severely understudied, with one hypothesis indicating a role in cell differentiation49,59. The RNA
pulldown analysis of miR-1205 targets in chapter 4 and the conclusion made by Huppi and
colleagues, led to the hypothesis that miR-1205 could play a role in cell lineage plasticity through
regulation of neuroendocrine differentiation of PCa cells. To this end, we were interested in
discovering whether miR-1205 will be involved in an emerging cell plasticity model of PCa
entailing the differentiation of luminal PCa epithelial cells to neuroendocrine PCa cells. To test
this hypothesis, we adapted an in vitro PCa cell

NED

model using androgen-sensitive LNCaP

cells162. We observed a significant decrease of miR-1205 expression in LNCaP-NED cells, when
compared to undifferentiated cells. Furthermore, we demonstrated that overexpression of miR-
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1205 leads to loss of Aurora kinase A (AurA) expression, which is amplified in NEPC tissue, and
neuroendocrine marker (NSE) expression, indicating that miR-1205 could be a driver of NED.
Lastly, we attempted to link a putative dendritic regulator and validated miR-1205 target,

FRYL

, to PCa cell NED. Based on the functions of the fry protein and its role in various cellular processes
such as cell polarization during morphogenesis, dendritic branching and tiling and spindle
organization during division, we hypothesized that FRYL may act in similar pathways due to high
sequence homologies of functional domains between fry and FRYL111. We examined the role of
FRYL for the first time in PCa tissue and cell models and discovered its overexpression in PCa
and NEPC. However, using the same in vitro PCa NED model, FRYL mRNA expression showed
a modest increase in LNCaP-NED cells when compared to undifferentiated LNCaP cells.
Furthermore, when FRYL was knocked out, we could not observe a significant loss of NED marker
or AurA expression, suggesting that FRYL alone is not a major regulator in NED of PCa cells.
However, it is important to stress that significant FRYL overexpression was observed in NEPC
and it may be that concurrent loss of FRYL and other binding partners are required for NED
regulation. Moreover, further examination on the role of FRYL in NED should be examined in
vivo or using a 3-D NEPC organoid model to determine whether putative FRYL regulation of NED
is dependent in a spatially organized environment. Nevertheless, we can conclude that miR-1205
regulates neural-associated pathways and may be clinically impactful for the aggressiveness of
NEPC. Further investigation into the neural-associated miR-1205 mRNA targets could further
elucidate novel regulatory pathways involved in cell lineage plasticity and NED. One proposed
experiment could include isolating miR-1205 molecular targets with RNA pull down experiments
and perform subsequent RNA sequencing to identify enriched targets in LNCaP-NED and
undifferentiated cells and further implicate the clinical relevance of miR-1205 in NED.
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In summary, this thesis revealed novel mechanisms regulated by PVT1-encoded miR-1205
in PCa. Given that initial evidence on the role of miR-1205 in PCa was not investigated before,
our work is among the first to discover that it is underexpressed in PCa and the first to characterize
basic biological functions regulated by miR-1205. Further investigation on the role of PVT1encoded miRNAs may reveal novel insights into the importance of this genomic locus that is often
altered in cancer.
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